At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	O
effects	O
on	O
locomotion	O
,	O
BD0000	T-0
,	O
BD0000	T-1
and	O
LR000	T-2
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	T-3
of	T-3
cocaine	B-Chemical
.	O

At	O
doses	T-3
where	O
alone	O
,	O
they	O
produced	O
no	O
significant	T-4
effects	T-4
on	O
locomotion	O
,	O
BD0000	T-0
,	O
BD0000	T-1
and	O
LR000	B-Chemical
significantly	T-6
attenuated	T-6
the	O
locomotor	O
stimulatory	T-5
effects	T-5
of	O
cocaine	T-2
.	O

At	O
doses	O
where	O
alone	O
,	O
they	O
produced	O
no	T-1
significant	T-1
effects	T-1
on	O
locomotion	O
,	O
BD0000	O
,	O
BD0000	B-Chemical
and	O
LR000	O
significantly	T-0
attenuated	T-0
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

At	O
doses	O
where	O
alone	O
,	O
they	T-2
produced	T-2
no	T-3
significant	T-3
effects	T-3
on	O
locomotion	O
,	O
BD0000	B-Chemical
,	O
BD0000	T-0
and	O
LR000	T-1
significantly	O
attenuated	O
the	O
locomotor	O
stimulatory	O
effects	O
of	O
cocaine	O
.	O

Since	O
AAP	O
,	O
AMI	O
and	O
DOX	O
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	T-0
by	T-0
GSPE	B-Chemical
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Since	O
AAP	O
,	O
AMI	O
and	O
DOX	B-Chemical
undergo	O
biotransformation	O
and	O
are	T-3
known	T-3
to	T-3
produce	T-0
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	T-1
by	T-1
GSPE	O
may	O
be	O
linked	O
to	O
both	O
inhibition	T-2
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Since	O
AAP	O
,	O
AMI	B-Chemical
and	O
DOX	O
undergo	O
biotransformation	O
and	O
are	O
known	O
to	T-0
produce	T-0
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	O
may	O
be	O
linked	T-1
to	T-1
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Since	O
AAP	B-Chemical
,	T-0
AMI	T-0
and	T-0
DOX	T-0
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	O
damaging	O
radicals	O
in	O
vivo	O
,	O
the	O
protection	O
by	O
GSPE	O
may	O
be	O
linked	O
to	O
both	O
inhibition	O
of	O
metabolism	O
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	O
radicals	O
.	O

Results	O
indicate	O
that	O
GSPE	O
preexposure	T-0
prior	T-0
to	O
AAP	O
,	O
AMI	O
and	O
DOX	B-Chemical
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Results	O
indicate	O
that	O
GSPE	O
preexposure	T-0
prior	O
to	O
AAP	O
,	O
AMI	B-Chemical
and	O
DOX	O
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

Results	O
indicate	T-1
that	O
GSPE	O
preexposure	T-2
prior	T-0
to	T-0
AAP	B-Chemical
,	O
AMI	O
and	O
DOX	O
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	T-3
DNA	O
fragmentation	O
.	O

Results	O
indicate	O
that	O
GSPE	B-Chemical
preexposure	T-0
prior	O
to	O
AAP	O
,	O
AMI	O
and	O
DOX	O
,	O
provided	O
near	O
complete	O
protection	O
in	O
terms	O
of	O
serum	O
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	O
reduced	O
DNA	O
fragmentation	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	T-0
gavaged	T-0
000	O
mg	O
/	O
Kg	O
GSPE	O
for	O
0	O
-	O
00	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	O
:	O
000	O
mg	O
/	O
Kg	O
for	O
00	O
h	O
;	O
AMI	O
:	O
00	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	B-Chemical
:	O
00	O
mg	O
/	O
Kg	O
for	O
00	O
h	O
)	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
000	O
mg	O
/	O
Kg	O
GSPE	O
for	O
0	O
-	O
00	O
days	O
followed	T-0
by	T-0
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	O
:	O
000	O
mg	O
/	O
Kg	O
for	O
00	O
h	O
;	O
AMI	B-Chemical
:	O
00	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
00	O
mg	O
/	O
Kg	O
for	O
00	O
h	O
)	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	T-2
gavaged	T-2
000	O
mg	O
/	O
Kg	O
GSPE	O
for	O
0	O
-	O
00	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	T-3
of	O
organ	O
specific	O
three	O
drugs	T-0
(	O
AAP	B-Chemical
:	O
000	T-1
mg	T-1
/	O
Kg	O
for	O
00	O
h	O
;	O
AMI	O
:	O
00	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
00	O
mg	O
/	O
Kg	O
for	O
00	O
h	O
)	O
.	O

For	O
the	O
cytoprotection	O
study	O
,	O
animals	O
were	O
orally	O
gavaged	O
000	T-0
mg	T-0
/	T-0
Kg	T-0
GSPE	B-Chemical
for	O
0	O
-	O
00	O
days	O
followed	O
by	O
i	O
.	O
p	O
.	O
injections	O
of	O
organ	O
specific	O
three	O
drugs	O
(	O
AAP	O
:	O
000	O
mg	O
/	O
Kg	O
for	O
00	O
h	O
;	O
AMI	O
:	O
00	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
four	O
days	O
;	O
DOX	O
:	O
00	O
mg	O
/	O
Kg	O
for	O
00	O
h	O
)	O
.	O

Two	O
patients	T-1
developed	T-2
acute	O
tubular	O
necrosis	O
,	O
characterized	T-3
clinically	O
by	T-4
acute	O
oliguric	O
renal	O
failure	O
,	O
while	O
they	O
were	O
receiving	T-0
a	O
combination	O
of	O
cephalothin	O
sodium	O
and	O
gentamicin	B-Chemical
sulfate	I-Chemical
therapy	T-5
.	O

Two	O
patients	O
developed	T-0
acute	O
tubular	O
necrosis	O
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	O
renal	O
failure	O
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	T-1
of	T-1
cephalothin	B-Chemical
sodium	I-Chemical
and	T-2
gentamicin	T-2
sulfate	T-2
therapy	O
.	O

Two	O
patients	O
developed	T-0
acute	O
tubular	O
necrosis	O
,	O
characterized	O
clinically	O
by	T-3
acute	T-3
oliguric	B-Disease
renal	I-Disease
failure	I-Disease
,	O
while	O
they	O
were	O
receiving	T-1
a	O
combination	O
of	O
cephalothin	O
sodium	O
and	O
gentamicin	O
sulfate	O
therapy	O
.	O

Two	O
patients	T-2
developed	T-2
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
,	O
characterized	O
clinically	O
by	O
acute	O
oliguric	O
renal	O
failure	O
,	O
while	O
they	O
were	O
receiving	O
a	O
combination	O
of	O
cephalothin	O
sodium	O
and	O
gentamicin	O
sulfate	O
therapy	T-1
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	T-0
Pain	O
Syndrome	O
(	O
CIPS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
side	T-2
effect	T-2
of	T-2
cyclosporine	O
or	O
tacrolimus	B-Chemical
and	O
is	O
accurately	O
diagnosed	T-1
by	T-1
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	O
Pain	O
Syndrome	O
(	O
CIPS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
side	T-0
effect	T-0
of	T-0
cyclosporine	B-Chemical
or	O
tacrolimus	O
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	T-0
Pain	O
Syndrome	O
(	O
CIPS	B-Disease
)	O
is	T-1
a	T-1
rare	T-1
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	O
or	O
tacrolimus	O
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

The	O
Calcineurin	O
-	O
inhibitor	O
Induced	T-0
Pain	B-Disease
Syndrome	O
(	O
CIPS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
side	O
effect	O
of	O
cyclosporine	O
or	O
tacrolimus	O
and	O
is	O
accurately	O
diagnosed	O
by	O
its	O
typical	O
presentation	O
,	O
magnetic	O
resonance	O
imaging	O
and	O
bone	O
scans	O
.	O

The	O
reduction	O
of	O
cyclosporine	O
-	O
or	O
tacrolimus	O
trough	O
levels	O
and	O
the	O
administration	O
of	O
calcium	O
channel	O
blockers	O
led	T-2
to	T-2
relief	T-1
of	T-1
pain	B-Disease
.	O

The	O
reduction	O
of	O
cyclosporine	O
-	O
or	O
tacrolimus	O
trough	O
levels	T-0
and	O
the	O
administration	T-2
of	T-2
calcium	B-Chemical
channel	O
blockers	O
led	O
to	O
relief	O
of	O
pain	O
.	O

The	O
reduction	T-0
of	O
cyclosporine	O
-	O
or	O
tacrolimus	B-Chemical
trough	O
levels	O
and	O
the	O
administration	T-1
of	O
calcium	O
channel	O
blockers	O
led	T-2
to	T-2
relief	T-2
of	T-2
pain	T-2
.	O

The	O
reduction	T-0
of	T-0
cyclosporine	B-Chemical
-	O
or	O
tacrolimus	O
trough	O
levels	O
and	O
the	O
administration	T-1
of	T-1
calcium	O
channel	O
blockers	O
led	O
to	O
relief	T-2
of	O
pain	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
00	O
mg	O
of	O
losartan	O
resulted	O
in	O
a	O
sudden	T-1
anuria	O
,	O
which	O
lasted	O
eight	O
hours	O
despite	T-2
high	T-0
-	T-0
dose	T-0
furosemide	O
and	O
amine	B-Chemical
infusion	T-3
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
00	O
mg	O
of	O
losartan	O
resulted	T-1
in	T-1
a	O
sudden	O
anuria	O
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	T-0
-	T-0
dose	T-0
furosemide	B-Chemical
and	O
amine	O
infusion	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	O
of	O
00	O
mg	O
of	O
losartan	O
resulted	T-0
in	T-0
a	O
sudden	T-2
anuria	B-Disease
,	O
which	T-1
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dose	O
furosemide	O
and	O
amine	O
infusion	O
.	O

Surprisingly	O
,	O
the	O
first	O
dose	T-0
of	T-0
00	O
mg	O
of	O
losartan	B-Chemical
resulted	T-1
in	T-1
a	O
sudden	O
anuria	O
,	O
which	O
lasted	O
eight	O
hours	O
despite	O
high	O
-	O
dose	O
furosemide	O
and	O
amine	O
infusion	O
.	O

Hypotension	O
following	O
the	O
initiation	O
of	O
tizanidine	O
in	O
a	O
patient	O
treated	T-1
with	T-1
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
for	O
chronic	T-0
hypertension	B-Disease
.	O

Hypotension	O
following	O
the	O
initiation	O
of	O
tizanidine	O
in	O
a	O
patient	O
treated	T-0
with	T-1
an	T-1
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	O
.	O

Hypotension	O
following	O
the	O
initiation	T-0
of	T-0
tizanidine	B-Chemical
in	T-1
a	T-1
patient	T-1
treated	O
with	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	O
.	O

Hypotension	B-Disease
following	T-1
the	T-1
initiation	T-1
of	T-1
tizanidine	O
in	O
a	O
patient	O
treated	O
with	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
for	O
chronic	O
hypertension	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
is	O
well	O
tolerated	O
and	O
shows	T-2
high	O
activity	O
in	T-0
metastatic	T-1
NSCLC	B-Disease
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-2
of	T-2
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	B-Chemical
is	T-0
well	T-0
tolerated	T-1
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-1
of	T-1
paclitaxel	O
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	O
is	O
well	T-0
tolerated	T-0
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	T-0
of	T-0
paclitaxel	B-Chemical
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
is	O
well	T-1
tolerated	T-1
and	O
shows	O
high	T-2
activity	T-2
in	O
metastatic	O
NSCLC	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
0	O
were	O
treated	T-2
with	T-2
a	O
combination	O
of	O
paclitaxel	O
(	O
000	O
mg	O
/	O
m	O
(	O
0	O
)	O
given	O
intravenously	O
in	O
0	O
hours	O
)	O
on	O
Day	O
0	O
,	O
cisplatin	O
(	O
000	O
mg	O
/	O
m	O
(	O
0	O
)	O
given	O
intravenously	O
in	O
0	O
hours	O
)	O
on	O
Day	O
0	O
,	O
and	O
gemcitabine	B-Chemical
(	T-1
000	T-1
mg	T-1
/	T-1
m	T-1
(	T-1
0	T-1
)	T-1
given	T-0
intravenously	T-0
in	O
00	O
minutes	O
)	O
on	O
Days	O
0	O
and	O
0	O
,	O
every	O
0	O
weeks	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
0	O
were	O
treated	O
with	O
a	O
combination	O
of	O
paclitaxel	O
(	O
000	O
mg	O
/	O
m	O
(	O
0	O
)	O
given	O
intravenously	O
in	O
0	O
hours	O
)	O
on	O
Day	O
0	O
,	O
cisplatin	B-Chemical
(	T-1
000	T-1
mg	T-1
/	T-1
m	T-1
(	T-1
0	T-1
)	T-1
given	T-0
intravenously	T-0
in	O
0	O
hours	O
)	O
on	O
Day	O
0	O
,	O
and	O
gemcitabine	O
(	O
000	O
mg	O
/	O
m	O
(	O
0	O
)	O
given	O
intravenously	O
in	O
00	O
minutes	O
)	O
on	O
Days	O
0	O
and	O
0	O
,	O
every	O
0	O
weeks	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	O
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
0	O
were	O
treated	O
with	O
a	O
combination	T-1
of	T-1
paclitaxel	B-Chemical
(	O
000	O
mg	O
/	O
m	O
(	O
0	O
)	O
given	T-0
intravenously	T-0
in	O
0	O
hours	O
)	O
on	O
Day	O
0	O
,	O
cisplatin	O
(	O
000	O
mg	O
/	O
m	O
(	O
0	O
)	O
given	O
intravenously	O
in	O
0	O
hours	O
)	O
on	O
Day	O
0	O
,	O
and	O
gemcitabine	O
(	O
000	O
mg	O
/	O
m	O
(	O
0	O
)	O
given	O
intravenously	O
in	O
00	O
minutes	O
)	O
on	O
Days	O
0	O
and	O
0	O
,	O
every	O
0	O
weeks	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	T-1
IV	T-1
NSCLC	B-Disease
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
0	O
were	O
treated	T-0
with	T-0
a	O
combination	O
of	O
paclitaxel	O
(	O
000	O
mg	O
/	O
m	O
(	O
0	O
)	O
given	O
intravenously	O
in	O
0	O
hours	O
)	O
on	O
Day	O
0	O
,	O
cisplatin	O
(	O
000	O
mg	O
/	O
m	O
(	O
0	O
)	O
given	O
intravenously	O
in	O
0	O
hours	O
)	O
on	O
Day	O
0	O
,	O
and	O
gemcitabine	O
(	O
000	O
mg	O
/	O
m	O
(	O
0	O
)	O
given	O
intravenously	O
in	O
00	O
minutes	O
)	O
on	O
Days	O
0	O
and	O
0	O
,	O
every	O
0	O
weeks	O
.	O

Paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	T-0
in	O
metastatic	T-1
nonsmall	B-Disease
cell	I-Disease
lung	I-Disease
carcinoma	I-Disease
.	O

Paclitaxel	T-0
,	O
cisplatin	T-1
,	O
and	O
gemcitabine	B-Chemical
combination	O
chemotherapy	T-2
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	O
in	O
metastatic	O
nonsmall	O
cell	O
lung	O
carcinoma	O
.	O

Paclitaxel	O
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	O
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	T-0
in	O
metastatic	O
nonsmall	O
cell	O
lung	O
carcinoma	O
.	O

Paclitaxel	B-Chemical
,	T-1
cisplatin	T-1
,	O
and	O
gemcitabine	O
combination	O
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	O
approach	T-0
in	O
metastatic	O
nonsmall	O
cell	O
lung	O
carcinoma	O
.	O

Ketamine	O
can	T-0
improve	T-0
morphine	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	B-Disease
pain	I-Disease
.	O

Ketamine	O
can	O
improve	T-1
morphine	O
analgesia	O
in	O
difficult	O
pain	B-Disease
syndromes	T-0
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Ketamine	O
can	O
improve	T-1
morphine	B-Chemical
analgesia	T-0
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Ketamine	B-Chemical
can	T-0
improve	T-0
morphine	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	O
(	O
0	O
.	O
00	O
mg	O
/	O
kg	O
or	O
0	O
.	O
00	O
mg	O
/	O
kg	O
)	O
was	O
given	T-1
to	T-1
00	O
cancer	O
patients	O
whose	O
pain	O
was	O
unrelieved	T-0
by	T-0
morphine	B-Chemical
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	O
(	O
0	O
.	O
00	O
mg	O
/	O
kg	O
or	O
0	O
.	O
00	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
00	O
cancer	O
patients	T-2
whose	T-2
pain	B-Disease
was	T-1
unrelieved	T-1
by	O
morphine	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	O
(	O
0	O
.	O
00	O
mg	O
/	O
kg	O
or	O
0	O
.	O
00	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
00	O
cancer	B-Disease
patients	T-0
whose	O
pain	O
was	O
unrelieved	O
by	O
morphine	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	B-Chemical
(	O
0	O
.	O
00	O
mg	O
/	O
kg	O
or	O
0	O
.	O
00	O
mg	O
/	O
kg	O
)	O
was	O
given	T-0
to	T-0
00	O
cancer	O
patients	O
whose	O
pain	O
was	O
unrelieved	O
by	O
morphine	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

The	O
fits	O
ceased	O
within	O
0	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	O
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	O
deficiency	O
secondary	T-0
to	T-0
isoniazid	B-Chemical
medication	T-1
.	O

The	O
fits	O
ceased	O
within	O
0	O
hours	O
of	O
administering	T-1
intramuscular	O
pyridoxine	O
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	B-Chemical
deficiency	O
secondary	O
to	O
isoniazid	O
medication	O
.	O

The	O
fits	O
ceased	O
within	O
0	O
hours	O
of	O
administering	T-1
intramuscular	T-1
pyridoxine	B-Chemical
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	O
deficiency	O
secondary	O
to	O
isoniazid	O
medication	O
.	O

The	O
fits	B-Disease
ceased	T-0
within	T-0
0	O
hours	O
of	O
administering	O
intramuscular	O
pyridoxine	O
,	O
suggesting	T-1
an	O
aetiology	O
of	O
pyridoxine	O
deficiency	O
secondary	O
to	O
isoniazid	O
medication	O
.	O

The	O
differential	O
effects	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
static	O
and	O
dynamic	O
hyperalgesia	O
suggest	T-2
that	T-2
the	O
two	O
types	T-0
of	T-0
hyperalgesia	B-Disease
are	T-1
mediated	T-1
by	T-1
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

The	O
differential	O
effects	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
static	T-0
and	T-0
dynamic	T-0
hyperalgesia	B-Disease
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	O
are	O
mediated	T-1
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

The	O
differential	O
effects	T-0
of	T-0
ketamine	T-1
and	T-1
lidocaine	B-Chemical
on	O
static	O
and	O
dynamic	O
hyperalgesia	O
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	O
are	O
mediated	O
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

The	O
differential	T-2
effects	T-2
of	T-0
ketamine	B-Chemical
and	O
lidocaine	O
on	O
static	O
and	O
dynamic	O
hyperalgesia	O
suggest	O
that	O
the	O
two	O
types	O
of	O
hyperalgesia	O
are	O
mediated	T-1
by	O
separate	O
mechanisms	O
and	O
have	O
a	O
distinct	O
pharmacology	O
.	O

Differential	O
effects	T-0
of	T-0
systemically	O
administered	O
ketamine	O
and	O
lidocaine	O
on	O
dynamic	O
and	O
static	O
hyperalgesia	O
induced	T-1
by	T-1
intradermal	O
capsaicin	B-Chemical
in	T-2
humans	T-2
.	O

Differential	O
effects	O
of	O
systemically	O
administered	T-2
ketamine	O
and	O
lidocaine	O
on	O
dynamic	T-1
and	T-1
static	T-1
hyperalgesia	B-Disease
induced	T-3
by	O
intradermal	O
capsaicin	O
in	T-0
humans	T-0
.	O

Differential	O
effects	T-1
of	T-1
systemically	O
administered	O
ketamine	O
and	O
lidocaine	B-Chemical
on	O
dynamic	O
and	O
static	O
hyperalgesia	O
induced	T-2
by	T-2
intradermal	O
capsaicin	O
in	O
humans	O
.	O

Differential	O
effects	O
of	O
systemically	T-1
administered	T-1
ketamine	B-Chemical
and	O
lidocaine	O
on	O
dynamic	O
and	O
static	O
hyperalgesia	O
induced	T-0
by	O
intradermal	O
capsaicin	O
in	O
humans	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	O
of	O
bromocriptine	O
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	O
of	T-2
this	T-2
agonist	T-2
at	T-0
peripheral	T-0
dopamine	B-Chemical
D0	O
receptors	T-1
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	O
of	O
bromocriptine	O
appears	T-1
to	O
predominate	O
and	O
to	T-0
mask	T-0
the	T-0
bradycardia	B-Disease
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	O
D0	O
receptors	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	O
of	O
bromocriptine	B-Chemical
appears	T-2
to	T-2
predominate	T-0
and	O
to	O
mask	T-1
the	O
bradycardia	O
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	O
D0	O
receptors	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	T-0
tachycardia	B-Disease
of	T-1
bromocriptine	T-1
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	O
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	O
D0	O
receptors	O
.	O

These	O
results	T-2
show	T-2
that	T-2
00	O
-	O
day	O
isoproterenol	O
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	O
-	O
induced	T-0
tachycardia	O
to	O
bradycardia	B-Disease
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	T-1
to	T-1
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

These	O
results	O
show	O
that	O
00	O
-	O
day	O
isoproterenol	O
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	O
bromocriptine	O
-	T-1
induced	T-1
tachycardia	B-Disease
to	T-2
bradycardia	T-2
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

These	O
results	O
show	O
that	O
00	O
-	O
day	O
isoproterenol	O
pretreatment	O
not	O
only	O
abolished	O
but	O
reversed	T-0
bromocriptine	B-Chemical
-	O
induced	T-1
tachycardia	O
to	O
bradycardia	O
,	O
an	O
effect	O
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

These	O
results	T-2
show	T-2
that	O
00	O
-	O
day	O
isoproterenol	B-Chemical
pretreatment	O
not	O
only	O
abolished	T-0
but	O
reversed	T-1
bromocriptine	O
-	O
induced	O
tachycardia	O
to	O
bradycardia	O
,	O
an	T-3
effect	T-3
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	O
beta	O
-	O
adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	O
of	O
autonomic	O
regulation	O
of	O
the	O
heart	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	O
-	O
induced	O
tachycardia	O
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	O
D0	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	T-0
by	T-0
0	O
-	O
day	O
isoproterenol	B-Chemical
pretreatment	T-1
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	O
-	O
induced	O
tachycardia	O
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	T-0
by	T-2
central	T-2
dopamine	B-Chemical
D0	T-1
receptor	T-1
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
0	O
-	O
day	O
isoproterenol	O
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	O
-	O
induced	T-0
tachycardia	B-Disease
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	O
by	O
central	O
dopamine	O
D0	O
receptor	O
activation	O
and	O
(	O
ii	O
)	O
reduced	O
by	O
0	O
-	O
day	O
isoproterenol	O
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

It	O
has	O
been	O
shown	O
that	O
bromocriptine	B-Chemical
-	T-3
induced	T-3
tachycardia	O
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	T-1
by	T-1
central	O
dopamine	O
D0	O
receptor	O
activation	T-2
and	O
(	O
ii	O
)	O
reduced	O
by	O
0	O
-	O
day	O
isoproterenol	O
pretreatment	O
,	O
supporting	O
therefore	O
the	O
hypothesis	O
that	O
this	O
effect	O
is	O
dependent	O
on	O
sympathetic	O
outflow	O
to	O
the	O
heart	O
.	O

When	O
activating	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	T-1
in	T-1
NO	B-Chemical
-	T-0
deficient	T-0
rats	O
.	O

When	O
activating	T-0
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	B-Chemical
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

When	O
activating	T-0
the	T-0
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

When	O
activating	T-0
the	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
with	O
its	O
substrate	O
ATP	O
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

Hemolysis	O
caused	O
by	O
TAM	O
was	O
not	T-1
preceded	T-1
by	T-1
the	O
leakage	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	T-0
of	T-0
hemolysis	B-Disease
,	O
according	O
to	O
the	O
effects	T-2
on	T-2
osmotic	O
fragility	O
curves	O
.	O

Hemolysis	O
caused	O
by	O
TAM	O
was	O
not	O
preceded	T-0
by	T-0
the	O
leakage	O
of	O
K	B-Chemical
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	O
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O

Hemolysis	O
caused	T-0
by	T-0
TAM	B-Chemical
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	O
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O

Hemolysis	B-Disease
caused	T-0
by	T-0
TAM	O
was	O
not	O
preceded	O
by	O
the	O
leakage	O
of	O
K	O
(	O
+	O
)	O
from	O
the	O
cells	O
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	O
mechanism	O
of	O
hemolysis	O
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	O
.	O

Tamoxifen	O
(	O
TAM	O
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	O
cancer	O
,	O
induces	T-0
changes	T-0
in	T-0
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	B-Disease
anemia	I-Disease
.	O

Tamoxifen	O
(	O
TAM	O
)	O
,	O
the	O
antiestrogenic	O
drug	O
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	T-0
of	T-0
breast	B-Disease
cancer	I-Disease
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	O
anemia	O
.	O

Tamoxifen	T-0
(	O
TAM	B-Chemical
)	O
,	T-1
the	T-1
antiestrogenic	T-1
drug	T-1
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	O
cancer	O
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	O
anemia	O
.	O

Tamoxifen	B-Chemical
(	O
TAM	O
)	O
,	O
the	O
antiestrogenic	O
drug	T-0
most	O
widely	O
prescribed	O
in	O
the	O
chemotherapy	O
of	O
breast	O
cancer	O
,	O
induces	T-2
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	O
and	O
hemolytic	O
anemia	O
.	O

Dopamine	O
turnover	O
ratios	O
(	O
DOPAC	O
:	O
DA	O
and	O
HVA	O
:	O
DA	B-Chemical
)	O
were	T-1
found	T-1
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	T-0
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Dopamine	O
turnover	O
ratios	O
(	O
DOPAC	O
:	O
DA	O
and	O
HVA	B-Chemical
:	O
DA	O
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	T-0
to	T-0
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Dopamine	O
turnover	T-1
ratios	T-1
(	O
DOPAC	B-Chemical
:	O
DA	O
and	O
HVA	O
:	O
DA	O
)	O
were	T-0
found	T-0
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	O
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Dopamine	B-Chemical
turnover	T-1
ratios	T-1
(	O
DOPAC	O
:	O
DA	O
and	O
HVA	O
:	O
DA	O
)	O
were	O
found	O
to	O
be	O
lower	O
in	O
those	O
animals	O
exposed	T-0
to	T-0
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	O
cage	O
counterparts	O
.	O

Apomorphine	O
,	O
a	O
nonselective	T-0
dopamine	O
agonist	O
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	T-1
hypothermia	O
,	O
and	O
to	O
produce	O
distinct	O
changes	T-2
to	T-2
dopamine	B-Chemical
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

Apomorphine	O
,	O
a	O
nonselective	O
dopamine	O
agonist	O
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	T-0
hypothermia	B-Disease
,	T-1
and	T-1
to	T-1
produce	T-1
distinct	O
changes	O
to	O
dopamine	O
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

Apomorphine	O
,	O
a	O
nonselective	O
dopamine	B-Chemical
agonist	I-Chemical
,	O
was	T-0
selected	T-0
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	O
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	O
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

Apomorphine	B-Chemical
,	O
a	O
nonselective	O
dopamine	O
agonist	O
,	O
was	T-0
selected	T-0
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	O
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	O
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	O
calcification	O
in	O
rats	T-2
treated	T-2
with	T-0
vitamin	O
D	O
plus	O
Warfarin	O
,	O
and	O
chemical	T-3
analysis	T-3
showed	O
that	O
the	O
protein	O
that	O
accumulated	T-1
was	O
indeed	O
not	O
gamma	B-Chemical
-	I-Chemical
carboxylated	I-Chemical
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	O
calcification	O
in	O
rats	O
treated	T-0
with	T-0
vitamin	O
D	O
plus	O
Warfarin	B-Chemical
,	O
and	O
chemical	O
analysis	O
showed	O
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	O
of	O
artery	O
calcification	O
in	O
rats	O
treated	T-1
with	T-1
vitamin	B-Chemical
D	I-Chemical
plus	T-2
Warfarin	O
,	O
and	O
chemical	O
analysis	O
showed	T-0
that	O
the	O
protein	O
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O

High	O
levels	O
of	O
matrix	O
Gla	O
protein	O
are	O
found	O
at	O
sites	T-0
of	T-0
artery	B-Disease
calcification	I-Disease
in	O
rats	O
treated	T-1
with	T-1
vitamin	O
D	O
plus	O
Warfarin	O
,	O
and	O
chemical	O
analysis	O
showed	T-2
that	T-2
the	O
protein	O
that	O
accumulated	T-3
was	O
indeed	O
not	O
gamma	O
-	O
carboxylated	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	O
D	O
treatment	O
enhance	O
the	O
extent	O
of	O
artery	O
calcification	O
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	O
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	B-Disease
inhibitor	T-1
known	T-1
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	O
D	O
treatment	O
enhance	O
the	O
extent	O
of	O
artery	O
calcification	O
in	O
rats	O
given	O
sufficient	O
doses	T-1
of	T-1
Warfarin	B-Chemical
to	O
inhibit	T-0
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	O
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
growth	O
and	O
vitamin	O
D	O
treatment	O
enhance	T-0
the	O
extent	O
of	O
artery	B-Disease
calcification	I-Disease
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	O
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	O
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

The	O
present	O
studies	O
demonstrate	T-1
that	O
growth	T-2
and	O
vitamin	B-Chemical
D	I-Chemical
treatment	T-0
enhance	T-3
the	T-3
extent	T-3
of	O
artery	O
calcification	O
in	O
rats	O
given	O
sufficient	O
doses	O
of	O
Warfarin	O
to	O
inhibit	O
gamma	O
-	O
carboxylation	O
of	O
matrix	O
Gla	O
protein	O
,	O
a	O
calcification	O
inhibitor	O
known	O
to	O
be	O
expressed	O
by	O
smooth	O
muscle	O
cells	O
and	O
macrophages	O
in	O
the	O
artery	O
wall	O
.	O

NRA0000	O
and	O
clozapine	O
significantly	O
shortened	O
the	O
phencyclidine	O
(	O
PCP	B-Chemical
)	O
-	T-1
induced	T-1
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

NRA0000	O
and	O
clozapine	O
significantly	O
shortened	T-1
the	T-1
phencyclidine	B-Chemical
(	O
PCP	O
)	O
-	O
induced	T-0
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

NRA0000	O
and	T-0
clozapine	B-Chemical
significantly	O
shortened	O
the	O
phencyclidine	O
(	O
PCP	O
)	O
-	O
induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

NRA0000	B-Chemical
and	O
clozapine	O
significantly	T-0
shortened	T-0
the	O
phencyclidine	O
(	O
PCP	O
)	O
-	O
induced	T-1
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

NRA0000	O
has	O
negligible	T-0
affinity	T-0
for	O
the	O
human	O
cloned	O
dopamine	O
D0	O
receptor	O
(	O
Ki	O
=	O
00	O
nM	O
)	O
,	O
rat	O
serotonin	O
(	O
0	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
0A	O
receptors	O
(	O
Ki	O
=	O
000	O
nM	O
)	O
and	O
rat	O
alpha0	O
adrenoceptor	O
(	O
Ki	O
=	O
000	O
nM	O
)	O
.	O

NRA0000	O
has	O
negligible	T-0
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	O
D0	O
receptor	O
(	O
Ki	O
=	O
00	O
nM	O
)	O
,	O
rat	O
serotonin	B-Chemical
(	O
0	O
-	O
HT	O
)	O
0A	O
receptors	O
(	O
Ki	O
=	O
000	O
nM	O
)	O
and	O
rat	O
alpha0	O
adrenoceptor	O
(	O
Ki	O
=	O
000	O
nM	O
)	O
.	O

NRA0000	O
has	O
negligible	T-1
affinity	T-1
for	T-1
the	O
human	O
cloned	O
dopamine	B-Chemical
D0	T-0
receptor	T-0
(	O
Ki	O
=	O
00	O
nM	O
)	O
,	O
rat	O
serotonin	O
(	O
0	O
-	O
HT	O
)	O
0A	O
receptors	O
(	O
Ki	O
=	O
000	O
nM	O
)	O
and	O
rat	O
alpha0	O
adrenoceptor	O
(	O
Ki	O
=	O
000	O
nM	O
)	O
.	O

NRA0000	B-Chemical
has	O
negligible	T-0
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	O
D0	O
receptor	O
(	O
Ki	O
=	O
00	O
nM	O
)	O
,	O
rat	O
serotonin	O
(	O
0	O
-	O
HT	O
)	O
0A	O
receptors	O
(	O
Ki	O
=	O
000	O
nM	O
)	O
and	O
rat	O
alpha0	O
adrenoceptor	O
(	O
Ki	O
=	O
000	O
nM	O
)	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	O
with	O
vinorelbine	O
(	O
VNB	O
)	O
or	O
gemcitabine	O
(	O
GEM	O
)	O
may	O
obtain	O
a	O
response	T-0
rate	T-0
of	O
00	O
-	O
00	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	B-Disease
and	T-2
improvement	T-2
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	T-0
with	T-0
vinorelbine	O
(	O
VNB	O
)	O
or	O
gemcitabine	O
(	O
GEM	B-Chemical
)	O
may	T-1
obtain	T-1
a	O
response	O
rate	O
of	O
00	O
-	O
00	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	O
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	T-1
with	T-1
vinorelbine	T-0
(	T-0
VNB	T-0
)	T-0
or	T-0
gemcitabine	B-Chemical
(	O
GEM	O
)	O
may	T-2
obtain	T-2
a	O
response	O
rate	O
of	O
00	O
-	O
00	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	O
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

Recent	O
reports	O
indicate	O
that	O
single	O
agent	O
therapy	T-0
with	T-0
vinorelbine	B-Chemical
(	O
VNB	O
)	O
or	O
gemcitabine	O
(	O
GEM	O
)	O
may	O
obtain	O
a	O
response	O
rate	O
of	O
00	O
-	O
00	O
%	O
in	O
elderly	O
patients	O
,	O
with	O
acceptable	O
toxicity	O
and	O
improvement	O
in	O
symptoms	O
and	O
quality	O
of	O
life	O
.	O

Due	O
to	O
the	O
risk	T-0
of	T-0
this	O
tachycardia	O
inducing	T-1
myocardial	O
ischemia	O
,	O
we	O
would	O
not	T-2
recommend	T-2
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	O
/	O
propofol	B-Chemical
/	O
mixtures	O
studied	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	O
inducing	O
myocardial	O
ischemia	O
,	O
we	T-1
would	T-1
not	T-1
recommend	T-1
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	T-0
of	T-0
the	T-0
ephedrine	B-Chemical
/	O
propofol	O
/	O
mixtures	O
studied	O
.	O

Due	O
to	O
the	O
risk	O
of	O
this	O
tachycardia	O
inducing	T-1
myocardial	B-Disease
ischemia	I-Disease
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	O
/	O
propofol	O
/	O
mixtures	O
studied	O
.	O

Due	O
to	O
the	O
risk	T-0
of	T-0
this	T-0
tachycardia	B-Disease
inducing	T-1
myocardial	O
ischemia	O
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	O
patients	O
of	O
any	O
of	O
the	O
ephedrine	O
/	O
propofol	O
/	O
mixtures	O
studied	O
.	O

The	O
addition	O
of	O
ephedrine	O
to	O
propofol	O
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	O
response	T-1
to	T-1
propofol	B-Chemical
at	T-2
all	T-2
doses	T-2
used	O
in	O
this	O
study	O
.	O

The	O
addition	O
of	O
ephedrine	O
to	O
propofol	O
appears	O
to	O
be	O
an	O
effective	O
method	O
of	T-2
obtunding	T-2
the	T-2
hypotensive	B-Disease
response	T-0
to	O
propofol	O
at	O
all	O
doses	O
used	T-1
in	O
this	O
study	O
.	O

The	O
addition	O
of	O
ephedrine	T-1
to	T-1
propofol	B-Chemical
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	O
response	O
to	O
propofol	O
at	O
all	O
doses	T-0
used	O
in	O
this	O
study	O
.	O

The	O
addition	O
of	O
ephedrine	B-Chemical
to	T-0
propofol	T-0
appears	O
to	O
be	O
an	O
effective	O
method	O
of	O
obtunding	O
the	O
hypotensive	O
response	O
to	O
propofol	O
at	O
all	O
doses	O
used	O
in	O
this	O
study	O
.	O

Cocaine	O
-	O
induced	T-0
mood	O
disorder	O
:	O
prevalence	O
rates	O
and	O
psychiatric	O
symptoms	T-1
in	O
an	O
outpatient	O
cocaine	B-Chemical
-	O
dependent	T-2
sample	O
.	O

Cocaine	O
-	O
induced	T-2
mood	O
disorder	O
:	O
prevalence	T-3
rates	T-3
and	T-0
psychiatric	B-Disease
symptoms	T-1
in	T-1
an	O
outpatient	O
cocaine	O
-	O
dependent	O
sample	O
.	O

Cocaine	O
-	O
induced	T-1
mood	B-Disease
disorder	I-Disease
:	T-0
prevalence	T-0
rates	T-0
and	O
psychiatric	O
symptoms	O
in	O
an	O
outpatient	O
cocaine	O
-	O
dependent	O
sample	O
.	O

Cocaine	B-Chemical
-	T-1
induced	T-1
mood	O
disorder	O
:	O
prevalence	O
rates	O
and	O
psychiatric	O
symptoms	O
in	O
an	O
outpatient	O
cocaine	O
-	O
dependent	O
sample	O
.	O

Tetrandrine	O
(	O
TET	O
)	O
and	O
fangchinoline	O
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	T-0
analogues	O
with	O
a	O
bisbenzylisoquinoline	B-Chemical
structure	O
.	O

Tetrandrine	O
(	O
TET	O
)	O
and	O
fangchinoline	T-1
(	O
FAN	B-Chemical
)	O
are	T-2
two	T-2
naturally	T-2
occurring	T-2
analogues	O
with	O
a	O
bisbenzylisoquinoline	O
structure	O
.	O

Tetrandrine	O
(	O
TET	O
)	O
and	T-0
fangchinoline	B-Chemical
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	O
structure	O
.	O

Tetrandrine	O
(	O
TET	B-Chemical
)	O
and	O
fangchinoline	O
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	T-0
a	T-0
bisbenzylisoquinoline	O
structure	O
.	O

Effects	O
of	O
tetrandrine	O
and	O
fangchinoline	O
on	O
experimental	O
thrombosis	T-1
in	O
mice	O
and	O
human	T-0
platelet	B-Disease
aggregation	I-Disease
.	O

Effects	T-1
of	T-1
tetrandrine	O
and	O
fangchinoline	O
on	O
experimental	T-0
thrombosis	B-Disease
in	O
mice	O
and	O
human	O
platelet	O
aggregation	O
.	O

Effects	T-1
of	T-1
tetrandrine	T-1
and	O
fangchinoline	B-Chemical
on	O
experimental	O
thrombosis	O
in	O
mice	O
and	O
human	O
platelet	O
aggregation	O
.	O

Effects	T-0
of	T-0
tetrandrine	B-Chemical
and	O
fangchinoline	O
on	O
experimental	O
thrombosis	O
in	O
mice	O
and	O
human	O
platelet	O
aggregation	O
.	O

A	O
high	O
percentage	O
of	O
kanamycin	O
-	O
colistin	O
and	O
povidone	O
-	O
iodine	O
irrigations	O
were	O
associated	T-0
with	T-2
erosive	T-2
cystitis	B-Disease
and	T-3
suggested	T-3
a	O
possible	O
complication	O
with	O
human	O
usage	O
.	O

A	O
high	O
percentage	O
of	O
kanamycin	O
-	O
colistin	T-3
and	T-3
povidone	B-Chemical
-	I-Chemical
iodine	I-Chemical
irrigations	T-2
were	O
associated	O
with	O
erosive	O
cystitis	O
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	T-0
.	O

A	O
high	O
percentage	O
of	O
kanamycin	T-2
-	T-2
colistin	B-Chemical
and	T-3
povidone	T-3
-	O
iodine	O
irrigations	O
were	O
associated	T-0
with	O
erosive	O
cystitis	O
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	T-1
.	O

A	O
high	O
percentage	T-2
of	T-2
kanamycin	B-Chemical
-	O
colistin	O
and	O
povidone	O
-	O
iodine	O
irrigations	O
were	O
associated	T-0
with	O
erosive	O
cystitis	O
and	O
suggested	O
a	O
possible	O
complication	O
with	O
human	O
usage	T-1
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	T-0
with	O
selegiline	O
and	O
L	T-1
-	T-1
dopa	T-1
was	O
associated	O
with	O
selective	O
systolic	T-2
orthostatic	T-2
hypotension	T-2
which	O
was	O
abolished	O
by	O
withdrawal	T-3
of	T-3
selegiline	B-Chemical
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	O
and	O
L	O
-	O
dopa	O
was	O
associated	T-1
with	T-1
selective	O
systolic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
which	T-0
was	T-0
abolished	O
by	O
withdrawal	O
of	O
selegiline	O
.	O

Recently	O
,	O
we	O
found	O
that	O
therapy	T-3
with	T-3
selegiline	O
and	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
was	T-2
associated	T-2
with	O
selective	O
systolic	T-0
orthostatic	T-0
hypotension	T-0
which	O
was	O
abolished	O
by	O
withdrawal	T-1
of	T-1
selegiline	T-1
.	O

Recently	O
,	O
we	O
found	T-4
that	T-4
therapy	T-1
with	O
selegiline	B-Chemical
and	O
L	O
-	O
dopa	O
was	T-0
associated	T-5
with	T-5
selective	O
systolic	T-2
orthostatic	T-2
hypotension	T-2
which	O
was	O
abolished	O
by	O
withdrawal	T-3
of	T-3
selegiline	T-3
.	O

A	O
single	O
MPEP	O
(	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	O
either	O
by	O
methamphetamine	O
(	O
00	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	T-0
veratridine	B-Chemical
(	O
000	O
microM	O
)	O
.	O

A	O
single	O
MPEP	O
(	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	T-0
either	T-0
by	T-0
methamphetamine	B-Chemical
(	O
00	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
000	O
microM	O
)	O
.	O

A	O
single	O
MPEP	O
(	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	B-Chemical
release	T-0
stimulated	O
either	O
by	O
methamphetamine	O
(	O
00	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
000	O
microM	O
)	O
.	O

A	O
single	O
MPEP	O
(	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	O
the	O
basal	O
extracellular	T-0
dopamine	B-Chemical
level	T-1
in	T-1
the	T-1
striatum	T-1
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	O
either	O
by	O
methamphetamine	O
(	O
00	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
000	O
microM	O
)	O
.	O

A	O
single	T-0
MPEP	B-Chemical
(	O
0	O
mg	O
/	O
kg	O
ip	O
)	O
injection	O
reduced	T-1
the	O
basal	O
extracellular	O
dopamine	O
level	O
in	O
the	O
striatum	O
,	O
as	O
well	O
as	O
dopamine	O
release	O
stimulated	O
either	O
by	O
methamphetamine	O
(	O
00	O
mg	O
/	O
kg	O
sc	O
)	O
or	O
by	O
intrastriatally	T-2
administered	T-2
veratridine	T-2
(	O
000	O
microM	O
)	O
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR0	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	O
dopaminergic	O
neurotoxicity	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	O
and	O
inhibition	T-1
of	T-1
hyperthermia	B-Disease
in	T-2
rats	T-2
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR0	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	O
dopaminergic	O
neurotoxicity	O
is	O
associated	O
with	O
a	O
decrease	T-0
in	T-0
dopamine	B-Chemical
outflow	O
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	O
action	O
of	O
MPEP	O
,	O
a	O
selective	O
mGluR0	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	T-0
dopaminergic	O
neurotoxicity	B-Disease
is	T-1
associated	T-1
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	O
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	T-0
action	T-0
of	O
MPEP	O
,	O
a	O
selective	O
mGluR0	O
antagonist	O
,	O
in	O
methamphetamine	B-Chemical
-	O
induced	O
dopaminergic	O
neurotoxicity	O
is	O
associated	O
with	O
a	O
decrease	T-1
in	T-1
dopamine	T-1
outflow	T-1
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

Neuroprotective	O
action	T-3
of	T-3
MPEP	B-Chemical
,	O
a	O
selective	T-1
mGluR0	O
antagonist	O
,	O
in	O
methamphetamine	O
-	O
induced	T-2
dopaminergic	O
neurotoxicity	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
dopamine	O
outflow	O
and	O
inhibition	O
of	O
hyperthermia	O
in	O
rats	O
.	O

In	O
ICH	O
induction	O
using	O
0	O
.	O
000	O
-	O
unit	O
collagenase	O
,	O
heparin	T-0
enhanced	T-0
the	T-0
hematoma	T-0
volume	T-0
0	O
.	O
0	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	T-1
the	T-1
bleeding	B-Disease
0	O
.	O
0	O
-	O
fold	O
.	O

In	O
ICH	O
induction	O
using	O
0	O
.	O
000	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	O
the	O
hematoma	O
volume	O
0	O
.	O
0	O
-	O
fold	O
over	O
that	O
seen	O
in	T-0
control	T-0
ICH	B-Disease
animals	T-1
and	O
the	O
bleeding	O
0	O
.	O
0	O
-	O
fold	O
.	O

In	O
ICH	O
induction	O
using	O
0	O
.	O
000	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	T-0
the	O
hematoma	B-Disease
volume	T-1
0	O
.	O
0	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	O
the	O
bleeding	O
0	O
.	O
0	O
-	O
fold	O
.	O

In	O
ICH	O
induction	T-0
using	O
0	O
.	O
000	O
-	O
unit	O
collagenase	O
,	O
heparin	B-Chemical
enhanced	T-1
the	O
hematoma	O
volume	O
0	O
.	O
0	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	O
the	O
bleeding	O
0	O
.	O
0	O
-	O
fold	O
.	O

In	O
ICH	B-Disease
induction	T-0
using	O
0	O
.	O
000	O
-	O
unit	O
collagenase	O
,	O
heparin	O
enhanced	O
the	O
hematoma	O
volume	O
0	O
.	O
0	O
-	O
fold	O
over	O
that	O
seen	O
in	O
control	O
ICH	O
animals	O
and	O
the	O
bleeding	O
0	O
.	O
0	O
-	O
fold	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
00	O
patients	O
who	O
received	O
docetaxel	O
alone	O
developed	O
VTE	O
,	O
whereas	O
0	O
of	O
00	O
patients	O
(	O
00	O
%	O
)	O
who	O
received	O
docetaxel	O
plus	O
thalidomide	O
developed	T-0
VTE	B-Disease
(	O
p	O
=	O
0	O
.	O
000	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
00	O
patients	O
who	O
received	O
docetaxel	O
alone	O
developed	O
VTE	O
,	O
whereas	O
0	O
of	O
00	O
patients	O
(	O
00	O
%	O
)	O
who	O
received	T-1
docetaxel	O
plus	O
thalidomide	B-Chemical
developed	T-0
VTE	T-0
(	O
p	O
=	O
0	O
.	O
000	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
00	O
patients	T-0
who	T-0
received	T-0
docetaxel	O
alone	O
developed	O
VTE	O
,	O
whereas	O
0	O
of	O
00	O
patients	O
(	O
00	O
%	O
)	O
who	O
received	T-1
docetaxel	B-Chemical
plus	T-2
thalidomide	T-2
developed	O
VTE	O
(	O
p	O
=	O
0	O
.	O
000	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
00	T-1
patients	T-1
who	O
received	O
docetaxel	O
alone	O
developed	T-0
VTE	B-Disease
,	O
whereas	O
0	T-2
of	T-2
00	T-2
patients	T-2
(	O
00	O
%	O
)	O
who	O
received	O
docetaxel	O
plus	O
thalidomide	O
developed	O
VTE	O
(	O
p	O
=	O
0	O
.	O
000	O
)	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
None	O
of	O
00	O
patients	T-1
who	O
received	T-0
docetaxel	B-Chemical
alone	O
developed	O
VTE	O
,	O
whereas	O
0	O
of	O
00	O
patients	T-2
(	O
00	O
%	O
)	O
who	O
received	O
docetaxel	O
plus	O
thalidomide	O
developed	O
VTE	O
(	O
p	O
=	O
0	O
.	O
000	O
)	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	T-1
with	O
docetaxel	O
alone	O
or	O
in	T-2
combination	T-2
with	T-2
thalidomide	B-Chemical
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	T-0
with	T-0
docetaxel	B-Chemical
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	T-0
prostate	B-Disease
cancer	I-Disease
who	O
were	O
treated	T-1
with	T-1
docetaxel	O
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	T-2
of	T-2
venous	T-0
thromboembolism	T-0
(	O
VTE	B-Disease
)	O
in	T-1
patients	T-1
with	T-1
advanced	T-1
androgen	T-1
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	O
with	O
docetaxel	O
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	T-0
of	T-0
venous	B-Disease
thromboembolism	I-Disease
(	T-1
VTE	T-1
)	T-1
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
who	O
were	O
treated	O
with	O
docetaxel	O
alone	O
or	O
in	O
combination	O
with	O
thalidomide	O
.	O

Nephrotoxicity	O
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	O
and	O
urea	O
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	T-0
(	O
GSH	B-Chemical
)	O
in	T-1
the	T-1
kidney	T-1
cortex	T-1
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	O
and	O
urea	O
in	O
the	O
plasma	O
and	O
reduced	T-0
glutathione	B-Chemical
(	O
GSH	O
)	O
in	T-1
the	T-1
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	T-0
by	O
measuring	T-1
the	O
concentrations	T-2
of	O
creatinine	O
and	O
urea	B-Chemical
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	O
was	O
assessed	O
by	O
measuring	O
the	O
concentrations	T-1
of	T-1
creatinine	B-Chemical
and	T-2
urea	T-2
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

Nephrotoxicity	B-Disease
was	T-0
assessed	T-0
by	O
measuring	O
the	O
concentrations	O
of	O
creatinine	O
and	O
urea	O
in	O
the	O
plasma	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
in	O
the	O
kidney	O
cortex	O
,	O
and	O
by	O
light	O
microscopic	O
examination	O
of	O
kidney	O
sections	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	O
renal	O
failure	O
induced	T-0
by	T-0
gentamicin	O
(	O
GM	O
)	O
nephrotoxicity	B-Disease
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	O
renal	O
failure	O
induced	T-0
by	T-0
gentamicin	T-0
(	O
GM	B-Chemical
)	O
nephrotoxicity	T-1
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	O
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	O
renal	O
failure	O
induced	T-0
by	T-0
gentamicin	B-Chemical
(	T-1
GM	T-1
)	T-1
nephrotoxicity	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	O
of	O
treatment	T-0
of	O
rats	O
with	O
gum	O
Arabic	O
on	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
induced	T-1
by	O
gentamicin	O
(	O
GM	O
)	O
nephrotoxicity	O
.	O

In	O
the	O
present	O
work	O
we	O
assessed	O
the	O
effect	T-0
of	T-0
treatment	T-0
of	O
rats	T-2
with	T-3
gum	B-Chemical
Arabic	I-Chemical
on	O
acute	O
renal	O
failure	O
induced	O
by	O
gentamicin	O
(	O
GM	O
)	O
nephrotoxicity	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	O
with	O
CPA	O
/	O
EE	O
compared	O
with	O
conventional	T-1
combined	T-1
oral	B-Chemical
contraceptives	I-Chemical
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	T-0
with	T-0
CPA	O
/	O
EE	B-Chemical
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	T-0
with	T-0
CPA	B-Chemical
/	O
EE	O
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	T-1
risk	T-1
of	T-1
venous	T-1
thromboembolism	T-1
(	O
VTE	B-Disease
)	O
associated	T-0
with	T-0
CPA	T-0
/	O
EE	O
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
an	O
increased	O
risk	T-0
of	T-0
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	O
)	O
associated	T-1
with	T-1
CPA	O
/	O
EE	O
compared	O
with	O
conventional	O
combined	O
oral	O
contraceptives	O
(	O
COCs	O
)	O
.	O

We	O
investigated	O
the	O
diagnostic	T-0
value	T-0
of	T-0
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	T-1
of	T-1
myocardial	T-1
damage	T-1
in	O
a	O
rat	O
model	O
of	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiomyopathy	O
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	T-3
of	T-3
cardiac	B-Disease
disorders	I-Disease
monitored	O
by	O
echocardiography	O
and	O
histological	T-2
examinations	T-2
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	T-0
value	T-0
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	T-1
of	T-1
myocardial	T-1
damage	O
in	O
a	O
rat	O
model	O
of	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	T-3
cardiomyopathy	B-Disease
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	T-2
examinations	T-2
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	T-2
value	T-2
of	T-2
cTnI	T-2
and	T-2
cTnT	T-2
for	O
the	O
diagnosis	O
of	O
myocardial	T-0
damage	T-0
in	T-0
a	T-0
rat	T-0
model	T-0
of	T-0
doxorubicin	T-0
(	O
DOX	B-Chemical
)	O
-	O
induced	T-1
cardiomyopathy	T-1
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	O
value	O
of	O
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	O
damage	O
in	O
a	O
rat	O
model	O
of	O
doxorubicin	B-Chemical
(	T-0
DOX	T-0
)	T-0
-	O
induced	T-1
cardiomyopathy	T-1
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

We	O
investigated	O
the	O
diagnostic	O
value	T-0
of	T-0
cTnI	O
and	O
cTnT	O
for	O
the	O
diagnosis	O
of	O
myocardial	B-Disease
damage	I-Disease
in	O
a	O
rat	O
model	O
of	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiomyopathy	O
,	O
and	O
we	O
examined	O
the	O
relationship	O
between	O
serial	O
cTnI	O
and	O
cTnT	O
with	O
the	O
development	O
of	O
cardiac	O
disorders	O
monitored	O
by	O
echocardiography	O
and	O
histological	O
examinations	O
in	O
this	O
model	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	O
effect	O
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	O
FK000	O
plus	O
SRL	B-Chemical
was	O
better	T-0
tolerated	T-0
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	O
effect	T-2
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	T-0
FK000	B-Chemical
plus	T-1
SRL	T-1
was	O
better	O
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	O
nephrotoxic	O
effect	T-0
of	T-0
CsA	O
plus	O
SRL	B-Chemical
,	O
whereas	O
FK000	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	O
synergistic	T-0
nephrotoxic	T-0
effect	T-1
of	T-1
CsA	B-Chemical
plus	O
SRL	O
,	O
whereas	O
FK000	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

CONCLUSION	O
:	O
This	O
rat	O
study	O
demonstrated	O
a	T-0
synergistic	T-0
nephrotoxic	B-Disease
effect	O
of	O
CsA	O
plus	O
SRL	O
,	O
whereas	O
FK000	O
plus	O
SRL	O
was	O
better	O
tolerated	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	O
with	O
either	O
FK000	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	T-1
with	T-1
FK000	O
plus	O
SRL	B-Chemical
when	O
compared	O
with	O
treatment	T-2
with	T-2
any	T-2
of	T-2
the	T-2
single	T-2
substances	T-2
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	O
with	O
either	O
FK000	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	T-0
with	T-0
FK000	B-Chemical
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	O
with	O
either	O
FK000	O
or	O
SRL	B-Chemical
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK000	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	T-0
of	T-0
the	T-0
single	T-0
substances	T-0
.	O

A	O
further	O
deterioration	O
was	O
seen	O
when	O
CsA	O
was	O
combined	T-0
with	T-0
either	O
FK000	B-Chemical
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK000	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

A	O
further	O
deterioration	T-1
was	T-1
seen	T-1
when	T-1
CsA	B-Chemical
was	T-2
combined	T-2
with	T-2
either	O
FK000	O
or	O
SRL	O
,	O
whereas	O
the	O
GFR	O
remained	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
FK000	O
plus	O
SRL	O
when	O
compared	O
with	O
treatment	O
with	O
any	O
of	O
the	O
single	O
substances	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	O
free	O
0	O
h	O
after	O
rizatriptan	O
,	O
compared	O
with	O
00	O
.	O
0	O
%	O
treated	T-0
with	T-0
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
rizatriptan	B-Chemical
being	T-1
superior	T-1
within	O
0	O
h	O
of	O
treatment	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	O
free	O
0	O
h	O
after	O
rizatriptan	O
,	O
compared	O
with	O
00	O
.	O
0	O
%	O
treated	T-0
with	T-0
ergotamine	O
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
rizatriptan	O
being	O
superior	O
within	O
0	O
h	O
of	O
treatment	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	O
free	O
0	O
h	O
after	O
rizatriptan	O
,	O
compared	O
with	O
00	O
.	O
0	O
%	O
treated	T-0
with	T-0
ergotamine	B-Chemical
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
rizatriptan	O
being	O
superior	O
within	O
0	O
h	O
of	O
treatment	O
.	O

Forty	O
-	O
nine	O
percent	O
of	O
patients	O
were	O
pain	O
free	O
0	O
h	O
after	T-0
rizatriptan	B-Chemical
,	O
compared	T-1
with	T-1
00	O
.	O
0	O
%	O
treated	O
with	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
rizatriptan	O
being	O
superior	O
within	O
0	O
h	O
of	O
treatment	O
.	O

Forty	O
-	O
nine	T-0
percent	T-0
of	T-0
patients	T-0
were	O
pain	B-Disease
free	O
0	O
h	O
after	O
rizatriptan	O
,	O
compared	O
with	O
00	O
.	O
0	O
%	O
treated	O
with	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
rizatriptan	O
being	O
superior	O
within	O
0	O
h	O
of	O
treatment	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	O
and	O
ESRD	O
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	O
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
0	O
months	O
postoperatively	O
,	O
and	T-1
a	T-1
higher	T-1
0	T-0
-	T-0
year	T-0
serum	T-0
creatinine	B-Chemical
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	O
and	O
ESRD	O
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	O
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	T-1
with	T-1
hepatorenal	B-Disease
syndrome	I-Disease
,	O
higher	T-2
percentage	T-2
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
0	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
0	O
-	O
year	O
serum	O
creatinine	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	O
and	O
ESRD	O
patients	O
had	O
higher	O
preoperative	T-0
serum	T-2
creatinine	B-Chemical
levels	T-1
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
0	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
0	O
-	O
year	O
serum	O
creatinine	O
.	O

Compared	T-2
with	T-2
control	T-0
patients	T-0
,	O
CRF	O
and	O
ESRD	B-Disease
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	O
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	T-1
with	T-1
hepatorenal	T-1
syndrome	T-1
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
0	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
0	O
-	O
year	O
serum	O
creatinine	O
.	O

Compared	O
with	O
control	O
patients	O
,	O
CRF	B-Disease
and	O
ESRD	O
patients	O
had	O
higher	T-0
preoperative	T-0
serum	T-0
creatinine	T-0
levels	T-0
,	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	O
syndrome	O
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
0	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
0	O
-	O
year	O
serum	O
creatinine	O
.	O

Patients	T-0
were	T-0
divided	T-0
into	T-0
three	O
groups	T-1
:	O
Controls	O
,	O
no	O
CRF	O
or	O
ESRD	O
,	O
n	O
=	O
000	O
;	O
CRF	O
,	O
sustained	O
serum	O
creatinine	O
>	O
0	O
.	O
0	O
mg	O
/	O
dl	O
,	O
n	T-2
=	T-2
00	T-2
;	T-2
and	T-2
ESRD	B-Disease
,	O
n	T-3
=	T-3
00	T-3
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	O
or	O
ESRD	O
,	O
n	O
=	O
000	O
;	O
CRF	O
,	O
sustained	T-1
serum	O
creatinine	B-Chemical
>	O
0	T-0
.	T-0
0	T-0
mg	T-0
/	T-0
dl	T-0
,	O
n	O
=	O
00	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
00	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	T-0
,	O
no	O
CRF	O
or	O
ESRD	O
,	O
n	O
=	O
000	O
;	O
CRF	B-Disease
,	O
sustained	O
serum	O
creatinine	O
>	O
0	O
.	O
0	O
mg	O
/	O
dl	O
,	O
n	O
=	O
00	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
00	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	T-0
,	O
no	O
CRF	O
or	O
ESRD	B-Disease
,	O
n	O
=	O
000	O
;	O
CRF	O
,	O
sustained	O
serum	O
creatinine	O
>	O
0	O
.	O
0	O
mg	O
/	O
dl	O
,	O
n	O
=	O
00	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
00	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	B-Disease
or	O
ESRD	T-0
,	T-0
n	T-0
=	T-0
000	T-0
;	O
CRF	O
,	O
sustained	O
serum	O
creatinine	O
>	O
0	O
.	O
0	O
mg	O
/	O
dl	O
,	O
n	O
=	O
00	O
;	O
and	O
ESRD	O
,	O
n	O
=	O
00	O
.	O

A	O
00	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	O
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
00th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	T-0
rheumatoid	B-Disease
arthritis	I-Disease
.	O

A	O
00	O
-	O
year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	O
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
00th	O
day	O
of	O
a	O
course	T-1
of	T-1
oral	T-1
sulphasalazine	B-Chemical
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
00	O
-	O
year	O
-	O
old	O
lady	O
developed	T-0
a	T-0
constellation	O
of	O
dermatitis	O
,	O
fever	T-1
,	O
lymphadenopathy	B-Disease
and	T-2
hepatitis	T-2
,	O
beginning	O
on	O
the	O
00th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
00	O
-	O
year	O
-	O
old	O
lady	O
developed	T-1
a	O
constellation	O
of	O
dermatitis	O
,	O
fever	B-Disease
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
00th	O
day	O
of	O
a	O
course	T-0
of	T-0
oral	T-0
sulphasalazine	T-0
for	T-0
sero	T-0
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

A	O
00	O
-	O
year	O
-	O
old	O
lady	O
developed	T-2
a	T-2
constellation	T-2
of	T-2
dermatitis	B-Disease
,	O
fever	T-1
,	O
lymphadenopathy	O
and	O
hepatitis	O
,	O
beginning	O
on	O
the	O
00th	O
day	O
of	O
a	O
course	O
of	O
oral	O
sulphasalazine	O
for	O
sero	O
-	O
negative	O
rheumatoid	O
arthritis	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	O
administration	O
include	O
chest	O
wall	O
rigidity	O
,	O
hypotension	O
,	O
respiratory	O
depression	O
,	O
and	T-0
bradycardia	B-Disease
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	O
administration	O
include	O
chest	O
wall	O
rigidity	O
,	O
hypotension	T-0
,	O
respiratory	B-Disease
depression	I-Disease
,	O
and	T-1
bradycardia	T-1
.	O

Various	T-2
reported	T-2
side	T-2
effects	T-2
of	O
fentanyl	O
administration	O
include	T-3
chest	T-0
wall	T-0
rigidity	T-0
,	O
hypotension	B-Disease
,	O
respiratory	T-1
depression	T-1
,	O
and	O
bradycardia	O
.	O

Various	O
reported	O
side	O
effects	O
of	O
fentanyl	O
administration	T-3
include	T-3
chest	B-Disease
wall	I-Disease
rigidity	I-Disease
,	O
hypotension	T-1
,	O
respiratory	T-2
depression	O
,	O
and	O
bradycardia	O
.	T-2

Various	O
reported	O
side	T-1
effects	T-1
of	T-0
fentanyl	B-Chemical
administration	T-2
include	O
chest	O
wall	O
rigidity	O
,	O
hypotension	O
,	O
respiratory	O
depression	O
,	O
and	O
bradycardia	O
.	O

Four	T-0
compounds	T-0
known	O
to	T-1
increase	T-1
QT	O
interval	O
and	O
cause	T-2
TDP	O
were	T-3
investigated	T-3
:	O
terfenadine	O
,	O
terodiline	O
,	O
cisapride	O
and	O
E0000	B-Chemical
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	O
TDP	O
were	O
investigated	O
:	O
terfenadine	O
,	O
terodiline	T-0
,	O
cisapride	B-Chemical
and	T-1
E0000	T-1
.	O

Four	O
compounds	T-2
known	O
to	O
increase	T-0
QT	O
interval	O
and	O
cause	T-1
TDP	O
were	O
investigated	T-3
:	O
terfenadine	O
,	O
terodiline	B-Chemical
,	O
cisapride	O
and	O
E0000	O
.	O

Four	O
compounds	T-0
known	T-0
to	T-0
increase	T-0
QT	O
interval	O
and	O
cause	O
TDP	O
were	O
investigated	O
:	O
terfenadine	B-Chemical
,	O
terodiline	O
,	O
cisapride	O
and	O
E0000	O
.	O

Four	O
compounds	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
cause	T-0
TDP	B-Disease
were	O
investigated	O
:	O
terfenadine	O
,	O
terodiline	O
,	O
cisapride	O
and	O
E0000	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	T-0
of	T-0
RS	B-Disease
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	T-0
influence	T-2
of	T-2
the	O
serotonin	B-Chemical
system	T-1
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	B-Chemical
antagonist	T-1
,	O
suggesting	T-0
the	T-0
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	B-Chemical
,	O
a	T-0
serotonin	T-0
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	O
of	O
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

The	O
underlying	O
mechanism	T-1
of	T-1
withdrawal	B-Disease
-	I-Disease
emergent	I-Disease
RS	I-Disease
in	O
the	O
present	O
case	O
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	O
profile	O
of	O
risperidone	O
,	O
a	O
serotonin	O
-	O
dopamine	O
antagonist	O
,	O
suggesting	O
the	O
pathophysiologic	O
influence	T-2
of	T-2
the	O
serotonin	O
system	O
in	O
the	O
development	O
of	O
RS	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD0000	O
,	O
BD0000	O
,	O
or	O
LR000	O
significantly	O
attenuated	T-1
cocaine	O
-	O
induced	T-2
convulsions	B-Disease
and	O
lethality	T-0
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD0000	O
,	O
BD0000	O
,	O
or	O
LR000	O
significantly	T-1
attenuated	T-1
cocaine	B-Chemical
-	O
induced	T-2
convulsions	T-2
and	O
lethality	T-3
.	O

In	O
behavioral	O
studies	O
,	O
pre	T-1
-	T-1
treatment	T-1
of	T-1
mice	T-1
with	O
BD0000	O
,	O
BD0000	T-0
,	O
or	O
LR000	B-Chemical
significantly	T-2
attenuated	T-2
cocaine	T-3
-	T-3
induced	T-3
convulsions	T-3
and	T-3
lethality	T-3
.	O

In	O
behavioral	T-1
studies	T-1
,	O
pre	O
-	O
treatment	T-2
of	O
mice	O
with	O
BD0000	O
,	O
BD0000	B-Chemical
,	O
or	O
LR000	O
significantly	O
attenuated	O
cocaine	O
-	O
induced	T-3
convulsions	O
and	O
lethality	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	T-2
BD0000	B-Chemical
,	O
BD0000	O
,	O
or	O
LR000	O
significantly	T-0
attenuated	T-0
cocaine	O
-	O
induced	T-1
convulsions	O
and	O
lethality	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	T-0
in	T-0
Swiss	O
Webster	O
mice	O
:	O
BD0000	O
(	O
0S	O
-	O
0	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
,	O
0	O
-	O
diazabicyclo	O
[	O
0	O
.	O
0	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD0000	O
(	O
0	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR000	B-Chemical
(	O
0R	O
,	O
0S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
-	O
(	O
0	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	T-2
receptor	T-2
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	T-1
in	O
Swiss	O
Webster	O
mice	O
:	O
BD0000	O
(	O
0S	T-0
-	T-0
0	T-0
-	T-0
[	T-0
0	T-0
-	T-0
(	T-0
0	T-0
,	T-0
0	T-0
-	T-0
dichlorophenyl	T-0
)	T-0
ethyl	T-0
]	O
-	O
0	O
,	O
0	O
-	O
diazabicyclo	O
[	O
0	O
.	O
0	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD0000	O
(	O
0	B-Chemical
-	I-Chemical
[	I-Chemical
0	I-Chemical
-	I-Chemical
(	I-Chemical
0	I-Chemical
,	I-Chemical
0	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
methylpiperazine	I-Chemical
)	O
,	O
and	O
LR000	O
(	O
0R	O
,	O
0S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
-	O
(	O
0	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD0000	O
(	O
0S	T-0
-	T-0
0	T-0
-	T-0
[	T-0
0	T-0
-	T-0
(	T-0
0	T-0
,	T-0
0	T-0
-	T-0
dichlorophenyl	T-0
)	T-0
ethyl	T-0
]	O
-	O
0	O
,	O
0	O
-	O
diazabicyclo	O
[	O
0	O
.	O
0	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD0000	B-Chemical
(	O
0	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR000	O
(	O
0R	O
,	O
0S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
-	O
(	O
0	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	T-0
in	O
Swiss	O
Webster	O
mice	O
:	O
BD0000	O
(	O
0S	B-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
[	I-Chemical
0	I-Chemical
-	I-Chemical
(	I-Chemical
0	I-Chemical
,	I-Chemical
0	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
0	I-Chemical
,	I-Chemical
0	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
0	I-Chemical
.	I-Chemical
0	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	O
,	O
BD0000	O
(	O
0	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR000	O
(	O
0R	O
,	O
0S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
-	O
(	O
0	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	O
ligands	O
with	O
antagonist	O
activity	O
were	O
evaluated	O
in	O
Swiss	O
Webster	O
mice	O
:	O
BD0000	B-Chemical
(	T-0
0S	T-0
-	T-0
0	T-0
-	T-0
[	T-0
0	T-0
-	T-0
(	T-0
0	T-0
,	T-0
0	T-0
-	T-0
dichlorophenyl	T-0
)	T-0
ethyl	O
]	O
-	O
0	O
,	O
0	O
-	O
diazabicyclo	O
[	O
0	O
.	O
0	O
.	O
0	O
]	O
nonane	O
)	O
,	O
BD0000	O
(	O
0	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
-	O
methylpiperazine	O
)	O
,	O
and	O
LR000	O
(	O
0R	O
,	O
0S	O
-	O
(	O
+	O
)	O
-	O
cis	O
-	O
N	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
-	O
(	O
0	O
-	O
pyrrolidinyl	O
)	O
cyclohexylamine	O
)	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	O
of	O
thrombotic	O
microangiopathy	O
,	O
malignant	O
hypertension	O
,	O
acute	O
interstitial	O
nephritis	O
,	O
and	T-0
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	O
of	O
thrombotic	O
microangiopathy	O
,	O
malignant	O
hypertension	O
,	O
acute	T-0
interstitial	B-Disease
nephritis	I-Disease
,	O
and	O
acute	O
tubular	O
necrosis	O
.	O

Native	O
kidney	O
specimens	O
included	O
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	T-2
of	T-2
thrombotic	T-0
microangiopathy	T-0
,	T-0
malignant	B-Disease
hypertension	I-Disease
,	T-1
acute	T-1
interstitial	T-1
nephritis	T-1
,	O
and	O
acute	O
tubular	O
necrosis	O
.	O

Native	O
kidney	O
specimens	O
included	T-2
a	O
wide	O
range	O
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	T-1
of	T-1
thrombotic	B-Disease
microangiopathy	I-Disease
,	O
malignant	T-0
hypertension	T-0
,	O
acute	O
interstitial	O
nephritis	O
,	O
and	O
acute	O
tubular	O
necrosis	O
.	O

Native	O
kidney	O
specimens	T-2
included	T-2
a	T-2
wide	T-2
range	T-2
of	T-1
glomerulopathies	B-Disease
as	T-0
well	T-0
as	T-0
cases	T-0
of	O
thrombotic	O
microangiopathy	O
,	O
malignant	O
hypertension	O
,	O
acute	O
interstitial	O
nephritis	O
,	O
and	O
acute	O
tubular	O
necrosis	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	O
or	O
mania	O
occurred	O
in	O
00	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
00	O
)	O
(	O
and	O
in	O
00	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	O
[	O
0	O
/	O
00	O
]	O
)	O
;	O
00	O
%	O
(	O
N	O
=	O
0	O
)	O
experienced	O
manic	O
episodes	O
,	O
and	O
00	O
%	O
(	O
N	O
=	O
0	O
)	O
experienced	T-0
hypomanic	B-Disease
episodes	T-1
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	O
or	O
mania	O
occurred	O
in	O
00	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
00	O
)	O
(	O
and	O
in	O
00	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	O
[	O
0	O
/	O
00	O
]	O
)	O
;	O
00	O
%	O
(	O
N	O
=	O
0	O
)	O
experienced	T-0
manic	B-Disease
episodes	T-1
,	O
and	O
00	O
%	O
(	O
N	O
=	O
0	O
)	O
experienced	O
hypomanic	O
episodes	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	O
or	O
mania	O
occurred	T-0
in	O
00	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
00	O
)	O
(	O
and	O
in	O
00	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	T-2
with	T-2
SSRIs	B-Chemical
[	O
0	O
/	O
00	O
]	O
)	O
;	O
00	O
%	O
(	O
N	O
=	O
0	O
)	O
experienced	T-1
manic	O
episodes	O
,	O
and	O
00	O
%	O
(	O
N	O
=	O
0	O
)	O
experienced	O
hypomanic	O
episodes	O
.	O

RESULTS	O
:	O
Switches	O
to	O
hypomania	O
or	O
mania	B-Disease
occurred	T-4
in	T-4
00	O
%	O
of	O
all	O
patients	T-1
(	O
N	O
=	O
00	O
)	O
(	O
and	O
in	O
00	O
%	O
of	O
the	O
subgroup	O
of	O
patients	T-2
treated	T-2
with	T-2
SSRIs	O
[	O
0	O
/	O
00	O
]	O
)	O
;	O
00	O
%	O
(	O
N	O
=	O
0	O
)	O
experienced	T-3
manic	O
episodes	O
,	O
and	O
00	O
%	O
(	O
N	O
=	O
0	O
)	O
experienced	O
hypomanic	O
episodes	O
.	O

RESULTS	O
:	O
Switches	T-0
to	T-0
hypomania	B-Disease
or	O
mania	O
occurred	O
in	O
00	O
%	O
of	O
all	O
patients	O
(	O
N	O
=	O
00	O
)	O
(	O
and	O
in	O
00	O
%	O
of	O
the	O
subgroup	O
of	O
patients	O
treated	O
with	O
SSRIs	O
[	O
0	O
/	O
00	O
]	O
)	O
;	O
00	O
%	O
(	O
N	O
=	O
0	O
)	O
experienced	O
manic	O
episodes	O
,	O
and	O
00	O
%	O
(	O
N	O
=	O
0	O
)	O
experienced	T-1
hypomanic	O
episodes	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	O
induced	T-0
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	T-1
by	T-1
GSPE	B-Chemical
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	O
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	B-Disease
in	T-0
the	T-0
respective	T-0
organs	T-0
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	T-0
,	O
such	O
as	O
,	O
AAP	O
,	O
AMI	O
and	O
DOX	B-Chemical
induced	T-1
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	T-2
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	O
as	O
,	O
AAP	T-0
,	T-0
AMI	B-Chemical
and	T-1
DOX	T-1
induced	O
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

Interestingly	O
,	O
all	O
the	O
drugs	O
,	O
such	T-1
as	T-1
,	O
AAP	B-Chemical
,	O
AMI	O
and	O
DOX	O
induced	T-0
apoptotic	O
death	O
in	O
addition	O
to	O
necrosis	O
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	O
blocked	O
by	O
GSPE	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	O
in	T-0
patients	T-0
with	O
acute	O
leukemia	O
treated	T-1
with	T-1
a	O
daunorubicin	O
(	O
DNR	B-Chemical
)	O
-	O
containing	O
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	O
cardiotoxicity	O
in	O
patients	O
with	O
acute	O
leukemia	O
treated	T-0
with	T-0
a	O
daunorubicin	B-Chemical
(	O
DNR	O
)	O
-	O
containing	T-1
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	T-0
indicator	O
of	O
anthracycline	O
-	O
induced	T-3
cardiotoxicity	O
in	O
patients	T-1
with	O
acute	B-Disease
leukemia	I-Disease
treated	T-4
with	T-4
a	O
daunorubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	O
of	O
anthracycline	O
-	O
induced	T-0
cardiotoxicity	B-Disease
in	T-1
patients	T-1
with	O
acute	O
leukemia	O
treated	O
with	O
a	O
daunorubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regimen	O
.	O

We	O
measured	O
the	O
plasma	O
level	O
of	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
to	O
determine	O
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	O
indicator	T-1
of	T-1
anthracycline	B-Chemical
-	O
induced	T-0
cardiotoxicity	O
in	O
patients	O
with	O
acute	O
leukemia	O
treated	O
with	O
a	O
daunorubicin	O
(	O
DNR	O
)	O
-	O
containing	O
regimen	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	T-1
with	T-1
propylthiouracil	O
in	O
whom	O
a	O
syndrome	T-0
of	T-0
pericarditis	O
,	O
fever	O
,	O
and	O
glomerulonephritis	B-Disease
developed	T-2
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	O
with	O
propylthiouracil	O
in	O
whom	O
a	O
syndrome	T-3
of	T-3
pericarditis	T-0
,	T-0
fever	B-Disease
,	T-1
and	T-1
glomerulonephritis	T-1
developed	T-2
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	O
with	O
propylthiouracil	O
in	O
whom	O
a	O
syndrome	T-0
of	T-0
pericarditis	B-Disease
,	T-1
fever	T-1
,	O
and	O
glomerulonephritis	O
developed	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	O
treated	T-0
with	T-0
propylthiouracil	B-Chemical
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	O
,	O
fever	O
,	O
and	O
glomerulonephritis	O
developed	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	B-Disease
treated	T-1
with	O
propylthiouracil	O
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	O
,	O
fever	O
,	O
and	O
glomerulonephritis	O
developed	T-0
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	O
be	O
extended	O
to	O
diazepam	O
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	T-1
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	T-0
the	T-0
GABA	B-Chemical
(	T-2
A	T-2
)	T-2
receptor	T-2
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	T-0
be	T-0
extended	T-0
to	T-0
diazepam	O
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	B-Chemical
,	O
suggesting	T-1
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	O
sensitivities	O
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	O
be	O
extended	T-0
to	T-0
diazepam	O
,	O
picrotoxin	B-Chemical
,	O
and	T-1
pentylenetetrazol	O
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	T-2
sensitivities	T-2
of	O
BS	O
and	O
BR	O
lines	O
to	O
beta	O
-	O
CCM	O
can	T-0
be	T-0
extended	T-3
to	O
diazepam	B-Chemical
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	T-1
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

Results	O
presented	O
here	O
show	O
that	O
the	O
differential	T-1
sensitivities	T-1
of	O
BS	O
and	O
BR	O
lines	T-0
to	T-0
beta	B-Chemical
-	I-Chemical
CCM	I-Chemical
can	O
be	O
extended	O
to	O
diazepam	O
,	O
picrotoxin	O
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	O
a	O
genetic	O
selection	O
of	O
a	O
general	O
sensitivity	O
and	O
resistance	O
to	O
several	O
ligands	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	T-0
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	O
-	O
induced	T-1
seizures	B-Disease
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	B-Chemical
-	T-1
induced	T-1
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	B-Chemical
-	O
and	O
pentylenetetrazol	O
-	O
induced	T-0
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	O
measured	O
diazepam	O
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	B-Chemical
-	O
induced	T-0
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	O
-	O
induced	O
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

We	T-0
measured	T-0
diazepam	B-Chemical
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	O
plus	O
-	O
maze	O
test	O
,	O
diazepam	O
-	O
induced	O
sedation	O
by	O
recording	O
the	O
vigilance	O
states	O
,	O
and	O
picrotoxin	O
-	O
and	O
pentylenetetrazol	O
-	O
induced	O
seizures	O
after	O
i	O
.	O
p	O
.	O
injections	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
0	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	B-Chemical
site	T-0
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	T-1
by	T-1
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
0	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	T-3
agonist	T-3
of	T-3
the	O
GABA	B-Chemical
(	T-0
A	T-0
)	T-0
receptor	T-0
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	T-0
of	T-0
methyl	O
beta	O
-	O
carboline	O
-	O
0	O
-	O
carboxylate	O
(	O
beta	B-Chemical
-	I-Chemical
CCM	I-Chemical
)	O
,	O
an	T-1
inverse	T-1
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	O
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	T-0
of	T-0
methyl	B-Chemical
beta	I-Chemical
-	I-Chemical
carboline	I-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	T-1
beta	T-1
-	T-1
CCM	T-1
)	T-1
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

Two	O
mouse	O
lines	O
were	O
selectively	O
bred	O
according	O
to	O
their	O
sensitivity	O
(	O
BS	O
line	O
)	O
or	O
resistance	O
(	O
BR	O
line	O
)	O
to	O
seizures	B-Disease
induced	T-0
by	O
a	O
single	O
i	O
.	O
p	O
.	O
injection	O
of	O
methyl	O
beta	O
-	O
carboline	O
-	O
0	O
-	O
carboxylate	O
(	O
beta	O
-	O
CCM	O
)	O
,	O
an	O
inverse	O
agonist	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
benzodiazepine	O
site	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
0	O
female	O
patients	O
who	O
developed	O
incontinence	O
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	O
and	O
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	T-1
effect	T-1
on	T-1
venlafaxine	B-Chemical
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
0	O
female	O
patients	O
who	O
developed	T-1
incontinence	O
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	T-0
and	T-0
sertraline	B-Chemical
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	T-2
effect	T-2
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
0	O
female	O
patients	O
who	T-0
developed	T-0
incontinence	O
secondary	O
to	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	B-Chemical
and	T-1
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
0	O
female	O
patients	O
who	O
developed	T-0
incontinence	T-0
secondary	O
to	T-1
the	T-1
selective	T-1
serotonin	B-Chemical
reuptake	O
inhibitors	O
paroxetine	O
and	O
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

In	O
the	O
present	O
paper	O
the	O
authors	O
describe	O
0	O
female	O
patients	O
who	O
developed	T-0
incontinence	B-Disease
secondary	T-1
to	T-1
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
paroxetine	O
and	O
sertraline	O
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	O
on	O
venlafaxine	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	O
of	O
a	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	O
to	T-1
treat	T-1
metastatic	T-1
NSCLC	B-Disease
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	T-0
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	O
of	O
a	O
paclitaxel	O
,	O
cisplatin	T-1
,	T-1
and	T-1
gemcitabine	B-Chemical
combination	T-2
to	O
treat	O
metastatic	O
NSCLC	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	T-2
determine	T-2
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	O
of	O
a	O
paclitaxel	O
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	O
combination	O
to	T-1
treat	T-1
metastatic	O
NSCLC	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	T-1
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	T-2
of	T-2
a	T-2
paclitaxel	B-Chemical
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	T-3
to	O
treat	O
metastatic	O
NSCLC	O
.	O

METHODS	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
,	O
response	O
rate	O
,	O
and	O
toxicity	B-Disease
of	O
a	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
combination	T-1
to	O
treat	T-0
metastatic	O
NSCLC	O
.	O

Pain	O
intensity	O
on	O
a	O
0	O
to	O
00	O
numerical	O
scale	O
;	O
nausea	O
and	O
vomiting	O
,	O
drowsiness	O
,	O
confusion	O
,	O
and	T-1
dry	B-Disease
mouth	I-Disease
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
0	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
00	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
00	O
minutes	O
(	O
T00	O
)	O
,	O
00	O
minutes	O
(	O
T00	O
)	O
,	O
000	O
minutes	O
(	O
T000	O
)	O
,	O
and	O
000	O
minutes	O
(	O
T000	O
)	O
.	T-0

Pain	T-2
intensity	T-2
on	O
a	O
0	O
to	O
00	O
numerical	O
scale	O
;	O
nausea	O
and	O
vomiting	O
,	O
drowsiness	T-0
,	T-0
confusion	B-Disease
,	T-1
and	T-1
dry	T-1
mouth	T-1
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
0	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
00	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
00	O
minutes	O
(	O
T00	O
)	O
,	O
00	O
minutes	O
(	O
T00	O
)	O
,	O
000	O
minutes	O
(	O
T000	O
)	O
,	O
and	O
000	O
minutes	O
(	O
T000	O
)	O
.	O

Pain	O
intensity	O
on	O
a	O
0	O
to	O
00	O
numerical	O
scale	O
;	O
nausea	O
and	O
vomiting	B-Disease
,	O
drowsiness	O
,	O
confusion	O
,	O
and	O
dry	O
mouth	O
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
0	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
00	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	T-0
of	T-0
drugs	O
(	O
T0	O
)	O
and	O
after	O
00	O
minutes	O
(	O
T00	O
)	O
,	O
00	O
minutes	O
(	O
T00	O
)	O
,	O
000	O
minutes	O
(	O
T000	O
)	O
,	O
and	O
000	O
minutes	O
(	O
T000	O
)	O
.	O

Pain	O
intensity	O
on	O
a	O
0	O
to	O
00	O
numerical	O
scale	O
;	O
nausea	B-Disease
and	O
vomiting	O
,	O
drowsiness	O
,	O
confusion	O
,	O
and	O
dry	O
mouth	O
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
0	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
00	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	T-0
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
00	O
minutes	O
(	O
T00	O
)	O
,	O
00	O
minutes	O
(	O
T00	O
)	O
,	O
000	O
minutes	O
(	O
T000	O
)	O
,	O
and	O
000	O
minutes	O
(	O
T000	O
)	O
.	O

Pain	B-Disease
intensity	O
on	O
a	O
0	O
to	O
00	O
numerical	T-1
scale	T-1
;	O
nausea	O
and	O
vomiting	O
,	O
drowsiness	O
,	O
confusion	O
,	O
and	O
dry	O
mouth	O
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
0	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
00	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	T-2
of	T-2
drugs	T-2
(	O
T0	O
)	O
and	O
after	O
00	O
minutes	O
(	O
T00	O
)	O
,	O
00	O
minutes	O
(	O
T00	O
)	O
,	O
000	O
minutes	O
(	O
T000	O
)	O
,	O
and	O
000	O
minutes	O
(	O
T000	O
)	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
,	O
such	O
as	O
ketamine	O
,	O
may	T-0
be	T-0
effective	T-0
in	T-0
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	B-Disease
pain	I-Disease
.	O

Animal	T-2
and	T-2
clinical	T-2
studies	T-2
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
,	O
such	O
as	O
ketamine	O
,	O
may	O
be	O
effective	T-3
in	T-3
improving	T-3
opioid	O
analgesia	O
in	T-1
difficult	O
pain	B-Disease
syndromes	T-0
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
antagonists	O
,	O
such	T-1
as	T-1
ketamine	B-Chemical
,	T-0
may	T-0
be	T-0
effective	T-0
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Animal	O
and	O
clinical	O
studies	O
have	O
suggested	O
that	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	B-Chemical
)	O
antagonists	T-0
,	O
such	O
as	O
ketamine	O
,	O
may	O
be	O
effective	O
in	O
improving	T-1
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

Animal	O
and	O
clinical	O
studies	T-1
have	O
suggested	T-2
that	T-2
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	O
)	O
antagonists	O
,	O
such	O
as	O
ketamine	O
,	O
may	O
be	O
effective	O
in	O
improving	O
opioid	O
analgesia	O
in	O
difficult	O
pain	O
syndromes	O
,	O
such	O
as	O
neuropathic	O
pain	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	O
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	T-1
outcome	T-1
in	T-1
acute	B-Disease
stroke	I-Disease
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	T-0
reduction	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	O
stroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	T-0
between	O
nimodipine	B-Chemical
-	O
induced	T-1
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	O
stroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	O
Intravenous	O
Nimodipine	O
West	O
European	O
Stroke	B-Disease
Trial	T-0
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	O
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	O
outcome	O
in	O
acute	O
stroke	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
The	T-0
Intravenous	T-0
Nimodipine	B-Chemical
West	O
European	O
Stroke	O
Trial	O
(	O
INWEST	O
)	O
found	O
a	O
correlation	O
between	O
nimodipine	O
-	O
induced	T-1
reduction	O
in	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
an	O
unfavorable	T-2
outcome	T-2
in	O
acute	O
stroke	O
.	O

We	O
have	O
examined	T-0
the	O
effect	O
of	O
systemic	O
administration	T-1
of	O
ketamine	O
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	O
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	O
induced	T-2
by	T-2
capsaicin	B-Chemical
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	O
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	T-0
(	O
dynamic	O
)	O
pain	O
and	O
punctate	O
-	O
evoked	T-1
(	O
static	O
)	O
hyperalgesia	B-Disease
induced	T-2
by	O
capsaicin	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	T-0
of	O
ketamine	O
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	T-1
(	O
dynamic	O
)	O
pain	B-Disease
and	O
punctate	O
-	O
evoked	T-2
(	O
static	O
)	O
hyperalgesia	O
induced	T-3
by	O
capsaicin	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	O
of	O
ketamine	T-2
and	T-2
lidocaine	B-Chemical
on	T-1
brush	T-1
-	O
evoked	O
(	O
dynamic	O
)	O
pain	O
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	O
induced	O
by	O
capsaicin	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
systemic	O
administration	T-1
of	O
ketamine	B-Chemical
and	O
lidocaine	O
on	O
brush	O
-	O
evoked	O
(	O
dynamic	O
)	O
pain	O
and	O
punctate	O
-	O
evoked	O
(	O
static	O
)	O
hyperalgesia	T-2
induced	T-0
by	T-0
capsaicin	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	O
with	O
newer	O
oral	O
contraceptives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	T-0
of	T-0
OC	B-Chemical
use	T-1
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	T-0
with	T-0
newer	O
oral	O
contraceptives	O
(	O
OC	B-Chemical
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	T-0
the	T-0
risk	T-0
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
associated	O
with	O
newer	O
oral	B-Chemical
contraceptives	I-Chemical
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	B-Disease
)	O
associated	T-0
with	T-0
newer	O
oral	O
contraceptives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

The	O
epidemiological	O
studies	O
that	O
assessed	O
the	O
risk	T-0
of	T-0
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	O
)	O
associated	O
with	O
newer	O
oral	O
contraceptives	O
(	O
OC	O
)	O
did	O
not	O
distinguish	O
between	O
patterns	O
of	O
OC	O
use	O
,	O
namely	O
first	O
-	O
time	O
users	O
,	O
repeaters	O
and	O
switchers	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	T-0
revealed	T-0
from	T-0
the	O
lowered	O
Km	O
value	T-1
for	T-1
ATP	B-Chemical
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	T-0
affinity	T-0
of	T-0
the	O
ATP	B-Chemical
-	O
binding	T-1
site	T-1
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	T-0
activity	T-0
of	T-0
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	O
from	O
hypertension	O
,	O
the	O
activity	T-0
of	T-0
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

After	O
recovery	T-0
from	T-0
hypertension	B-Disease
,	O
the	O
activity	O
of	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
increased	O
,	O
due	O
to	O
higher	O
affinity	O
of	O
the	O
ATP	O
-	O
binding	O
site	O
,	O
as	O
revealed	O
from	O
the	O
lowered	O
Km	O
value	O
for	O
ATP	O
.	O

During	O
activation	O
with	O
Na	O
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	O
(	O
Na	O
)	O
increased	O
by	O
00	O
%	O
,	O
indicating	O
a	T-1
profound	T-1
decrease	T-1
in	O
the	O
affinity	O
of	O
the	O
Na	O
+	O
-	O
binding	T-0
site	O
in	O
NO	B-Chemical
-	O
deficient	O
rats	O
.	O

During	O
activation	O
with	O
Na	O
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	O
(	O
Na	O
)	O
increased	O
by	O
00	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	T-1
in	O
the	O
affinity	T-0
of	T-0
the	T-0
Na	B-Chemical
+	O
-	O
binding	T-2
site	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

During	O
activation	O
with	O
Na	O
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	T-0
(	O
Na	B-Chemical
)	O
increased	T-1
by	T-1
00	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	O
+	O
-	O
binding	O
site	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

During	T-0
activation	T-0
with	O
Na	O
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	T-1
the	T-1
K	B-Chemical
(	O
Na	O
)	O
increased	T-2
by	T-2
00	O
%	O
,	O
indicating	O
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	O
+	O
-	O
binding	O
site	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

During	O
activation	T-2
with	T-2
Na	B-Chemical
+	O
,	O
the	O
Vmax	O
remained	O
unchanged	O
,	O
however	O
the	O
K	O
(	O
Na	O
)	O
increased	O
by	O
00	O
%	O
,	O
indicating	T-1
a	O
profound	O
decrease	O
in	O
the	O
affinity	O
of	O
the	O
Na	O
+	O
-	O
binding	O
site	O
in	O
NO	O
-	O
deficient	O
rats	O
.	O

NRA0000	O
and	O
clozapine	O
antagonized	O
locomotor	O
hyperactivity	O
induced	T-0
by	T-0
methamphetamine	O
(	O
MAP	B-Chemical
)	O
in	O
mice	O
.	O

NRA0000	O
and	O
clozapine	O
antagonized	T-0
locomotor	O
hyperactivity	O
induced	T-1
by	T-1
methamphetamine	B-Chemical
(	O
MAP	O
)	O
in	O
mice	O
.	O

NRA0000	O
and	O
clozapine	O
antagonized	T-0
locomotor	T-0
hyperactivity	B-Disease
induced	T-1
by	T-1
methamphetamine	O
(	O
MAP	O
)	O
in	O
mice	O
.	O

NRA0000	T-0
and	T-0
clozapine	B-Chemical
antagonized	O
locomotor	O
hyperactivity	O
induced	T-1
by	T-1
methamphetamine	O
(	O
MAP	O
)	O
in	O
mice	O
.	O

NRA0000	B-Chemical
and	T-0
clozapine	O
antagonized	T-1
locomotor	T-1
hyperactivity	T-1
induced	O
by	O
methamphetamine	O
(	O
MAP	O
)	O
in	O
mice	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
GEM	O
and	O
VNB	O
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	T-1
receiving	T-1
cisplatin	B-Chemical
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
GEM	O
and	O
VNB	O
in	O
elderly	O
patients	T-0
with	T-0
advanced	T-1
NSCLC	B-Disease
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	T-0
efficacy	T-0
and	T-0
toxicity	T-0
of	T-0
the	O
combination	O
of	O
GEM	O
and	O
VNB	B-Chemical
in	T-1
elderly	O
patients	T-2
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	T-0
of	O
the	O
combination	T-1
of	T-1
GEM	B-Chemical
and	T-2
VNB	T-2
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	T-0
toxicity	B-Disease
of	T-1
the	T-1
combination	T-1
of	O
GEM	O
and	O
VNB	O
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	O
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	O
were	O
assessed	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	T-1
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	T-0
have	T-0
less	T-0
inflammation	B-Disease
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	T-0
larger	T-0
hematomas	B-Disease
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	O
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	T-0
hemodilution	B-Disease
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	O
-	O
treated	O
rats	O
exhibited	T-0
evidence	O
of	O
impaired	B-Disease
blood	I-Disease
clotting	I-Disease
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	T-1
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

Fucoidan	B-Chemical
-	T-1
treated	T-1
rats	T-1
exhibited	O
evidence	O
of	O
impaired	O
blood	O
clotting	O
and	O
hemodilution	O
,	O
had	O
larger	O
hematomas	O
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	O
in	O
the	O
vicinity	O
of	O
the	O
hematoma	O
after	O
three	O
days	O
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	T-0
administration	T-0
(	O
00	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
mice	O
showed	O
the	O
inhibition	T-1
of	T-1
thrombosis	O
by	O
00	O
%	O
and	O
00	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	O
(	O
ASA	B-Chemical
,	O
00	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
00	O
%	O
inhibition	O
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	T-2
(	O
00	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
mice	O
showed	O
the	O
inhibition	T-0
of	O
thrombosis	O
by	O
00	O
%	O
and	O
00	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	B-Chemical
acid	I-Chemical
(	O
ASA	O
,	O
00	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
00	O
%	O
inhibition	T-1
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	T-0
(	O
00	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
mice	O
showed	O
the	O
inhibition	T-2
of	O
thrombosis	B-Disease
by	O
00	O
%	O
and	O
00	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	O
(	O
ASA	O
,	O
00	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
00	O
%	O
inhibition	T-1
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	T-2
(	O
00	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	O
TET	O
and	O
FAN	B-Chemical
in	O
mice	O
showed	O
the	O
inhibition	T-3
of	O
thrombosis	T-1
by	O
00	O
%	O
and	O
00	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	O
(	O
ASA	O
,	O
00	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
00	O
%	O
inhibition	O
.	O

In	O
the	O
in	O
vivo	O
study	O
,	O
the	O
administration	T-2
(	O
00	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
of	T-0
TET	B-Chemical
and	T-1
FAN	O
in	O
mice	O
showed	O
the	O
inhibition	T-3
of	O
thrombosis	O
by	O
00	O
%	O
and	O
00	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	O
(	O
ASA	O
,	O
00	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
a	O
positive	O
control	O
,	O
showed	O
only	O
00	O
%	O
inhibition	T-4
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	T-1
(	O
seizure	B-Disease
kindling	T-0
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	T-2
neuroactive	T-2
steroid	T-2
that	O
positively	O
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	T-3
of	T-3
cocaine	T-0
engendered	T-1
by	T-1
repeated	T-1
cocaine	B-Chemical
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	T-0
of	T-0
cocaine	B-Chemical
engendered	T-1
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	T-0
to	T-0
evaluate	T-0
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	T-1
modulate	T-1
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	B-Chemical
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	O
neuroactive	O
steroid	O
that	O
positively	O
modulate	T-1
the	T-1
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	T-0
against	T-0
the	T-0
increase	T-0
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
two	O
endogenous	O
and	O
one	O
synthetic	T-1
neuroactive	T-1
steroid	B-Chemical
that	O
positively	T-2
modulate	T-2
the	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
(	O
A	O
)	O
)	O
receptor	O
against	O
the	O
increase	O
in	O
sensitivity	O
to	O
the	O
convulsant	O
effects	O
of	O
cocaine	O
engendered	O
by	O
repeated	O
cocaine	O
administration	O
(	O
seizure	O
kindling	O
)	O
.	O

Neither	O
L	T-0
-	T-0
arginine	T-0
transport	T-0
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
vs	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
pmol	O
/	O
00	O
000	O
cells	O
per	O
0	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
000	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
00	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
vs	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	T-1
affected	T-1
by	T-1
short	T-1
-	T-1
term	T-1
cortisol	B-Chemical
treatment	T-2
.	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
vs	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
pmol	O
/	O
00	O
000	O
cells	O
per	O
0	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
000	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
00	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
vs	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	T-0
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	T-1
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
vs	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
pmol	O
/	O
00	O
000	O
cells	O
per	O
0	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	T-0
-	T-0
arginine	T-0
concentration	T-0
of	O
000	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
00	O
minutes	O
,	O
placebo	T-1
vs	T-1
active	T-1
,	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
vs	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	B-Chemical
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
vs	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
pmol	O
/	O
00	O
000	O
cells	O
per	O
0	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	T-0
of	T-0
000	O
micromol	O
/	O
L	O
)	O
nor	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	T-1
in	O
the	O
forearm	O
(	O
at	O
00	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
vs	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

Neither	O
L	O
-	O
arginine	O
transport	O
into	O
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
vs	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
pmol	O
/	O
00	O
000	O
cells	O
per	O
0	O
minutes	O
,	O
respectively	O
,	O
at	T-0
an	T-0
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
concentration	T-1
of	O
000	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
00	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
vs	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

Neither	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
transport	T-0
into	T-0
mononuclear	O
cells	O
(	O
placebo	O
vs	O
active	O
,	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
vs	O
00	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
0	O
pmol	O
/	O
00	O
000	O
cells	O
per	O
0	O
minutes	O
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	O
of	O
000	O
micromol	O
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	O
(	O
at	O
00	O
minutes	O
,	O
placebo	O
vs	O
active	O
,	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
vs	O
0	O
000	O
000	O
+	O
/	O
-	O
000	O
000	O
disintegrations	O
per	O
minute	O
)	O
was	O
affected	O
by	O
cortisol	O
treatment	O
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	O
is	O
not	O
affected	O
by	O
short	O
-	O
term	O
cortisol	O
treatment	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	T-1
PCOS	B-Disease
although	T-0
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	T-0
risk	T-0
of	T-0
VTE	O
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	B-Disease
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	T-1
of	T-1
CPA	O
/	O
EE	O
in	O
women	O
with	O
acne	B-Disease
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	T-0
by	T-0
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	T-0
use	T-0
of	T-0
CPA	O
/	O
EE	B-Chemical
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	O
risk	O
of	O
VTE	O
associated	O
with	O
the	O
use	T-0
of	T-0
CPA	B-Chemical
/	O
EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
demonstrated	O
an	O
increased	T-0
risk	T-0
of	T-0
VTE	B-Disease
associated	O
with	O
the	O
use	O
of	O
CPA	O
/	O
EE	O
in	O
women	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
although	O
residual	O
confounding	O
by	O
indication	O
cannot	O
be	O
excluded	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	T-1
analysis	T-1
and	T-1
case	T-1
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	T-2
00	T-2
and	T-2
00	T-2
years	T-2
with	T-2
acne	T-2
,	O
hirsutism	O
or	O
PCOS	O
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	T-0
with	T-0
CPA	O
/	O
EE	B-Chemical
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
00	O
and	O
00	O
years	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	T-0
with	T-0
CPA	B-Chemical
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
00	O
and	O
00	O
years	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	O
to	O
estimate	O
the	O
risk	T-0
of	O
VTE	B-Disease
associated	O
with	O
CPA	O
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	T-0
analysis	T-0
and	T-0
case	T-0
-	T-0
control	T-0
study	T-0
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
00	O
and	O
00	O
years	O
with	O
acne	O
,	O
hirsutism	O
or	O
PCOS	B-Disease
to	T-2
estimate	T-2
the	T-1
risk	T-1
of	O
VTE	O
associated	O
with	O
CPA	O
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	T-2
Practice	T-2
Research	T-2
Database	T-2
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	T-0
study	T-0
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	O
00	O
and	O
00	O
years	O
with	O
acne	O
,	O
hirsutism	B-Disease
or	O
PCOS	O
to	O
estimate	O
the	O
risk	T-1
of	T-1
VTE	O
associated	O
with	O
CPA	O
/	O
EE	O
.	O

METHODS	O
:	O
Using	O
the	O
General	O
Practice	O
Research	O
Database	O
we	O
conducted	O
a	O
cohort	O
analysis	O
and	O
case	O
-	O
control	O
study	O
nested	O
within	O
a	O
population	O
of	O
women	O
aged	O
between	T-0
00	T-0
and	T-0
00	T-0
years	T-0
with	T-0
acne	B-Disease
,	O
hirsutism	T-1
or	T-1
PCOS	T-1
to	O
estimate	O
the	O
risk	O
of	O
VTE	O
associated	O
with	O
CPA	O
/	O
EE	O
.	O

The	O
most	O
common	O
adverse	T-0
events	T-0
(	O
incidence	O
>	O
or	O
=	O
0	O
%	O
in	O
one	O
group	O
)	O
after	T-1
rizatriptan	T-1
and	T-1
ergotamine	T-1
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
,	O
nausea	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
and	O
somnolence	B-Disease
(	T-2
0	T-2
.	T-2
0	T-2
and	T-2
0	T-2
.	T-2
0	T-2
%	T-2
)	T-2
.	O

The	O
most	O
common	O
adverse	T-1
events	T-1
(	O
incidence	O
>	O
or	O
=	O
0	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	O
and	O
ergotamine	O
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
,	O
nausea	B-Disease
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
and	T-0
somnolence	T-0
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
.	O

The	O
most	O
common	O
adverse	T-0
events	T-0
(	O
incidence	O
>	O
or	O
=	O
0	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	O
and	O
ergotamine	O
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	B-Disease
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
,	O
nausea	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
and	O
somnolence	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
.	O

The	O
most	O
common	O
adverse	T-0
events	T-0
(	O
incidence	O
>	O
or	O
=	O
0	O
%	O
in	O
one	O
group	O
)	O
after	O
rizatriptan	O
and	O
ergotamine	T-1
/	O
caffeine	B-Chemical
,	O
respectively	T-2
,	O
were	O
dizziness	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
,	O
nausea	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
and	O
somnolence	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
.	O

The	T-1
most	T-1
common	T-1
adverse	T-1
events	T-1
(	O
incidence	O
>	O
or	O
=	O
0	O
%	O
in	O
one	O
group	O
)	O
after	T-0
rizatriptan	O
and	O
ergotamine	B-Chemical
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
,	O
nausea	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
and	O
somnolence	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
or	O
=	O
0	O
%	O
in	O
one	O
group	O
)	O
after	T-0
rizatriptan	B-Chemical
and	T-1
ergotamine	T-1
/	O
caffeine	O
,	O
respectively	O
,	O
were	O
dizziness	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
,	O
nausea	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
and	O
somnolence	O
(	O
0	O
.	O
0	O
and	O
0	O
.	O
0	O
%	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	T-3
to	T-3
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	T-2
with	T-2
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	T-0
or	T-0
photophobia	B-Disease
and	T-1
for	T-1
patients	T-1
with	O
normal	O
function	O
0	O
h	O
after	O
drug	O
intake	T-4
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	T-1
nausea	T-1
,	T-1
vomiting	T-1
,	O
phonophobia	B-Disease
or	O
photophobia	T-2
and	O
for	O
patients	O
with	O
normal	O
function	O
0	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	O
with	T-0
no	T-0
nausea	B-Disease
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	O
with	O
normal	O
function	O
0	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	T-0
to	T-0
ergotamine	O
/	O
caffeine	B-Chemical
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	O
with	O
normal	O
function	O
0	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
.	O

Rizatriptan	O
was	O
also	O
superior	T-1
to	T-1
ergotamine	B-Chemical
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	T-0
with	O
normal	O
function	O
0	O
h	O
after	O
drug	O
intake	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
.	O

Rizatriptan	B-Chemical
was	T-1
also	T-1
superior	T-1
to	O
ergotamine	O
/	O
caffeine	O
in	O
the	O
proportions	O
of	O
patients	O
with	O
no	O
nausea	O
,	O
vomiting	O
,	O
phonophobia	O
or	O
photophobia	O
and	O
for	O
patients	O
with	O
normal	O
function	O
0	O
h	O
after	T-0
drug	T-0
intake	T-0
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	O
failure	O
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	T-1
from	T-1
exencephaly	T-0
to	O
anencephaly	B-Disease
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	T-0
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	O
failure	O
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	T-1
from	O
exencephaly	B-Disease
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	T-0
circulatory	T-0
failure	T-2
and	T-2
/	T-2
or	T-2
hemorrhaging	T-2
in	T-2
various	T-2
parts	T-2
of	O
the	O
exencephalic	B-Disease
head	O
,	O
leading	T-3
to	T-3
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	T-3
of	T-3
the	O
exencephalic	O
neural	O
tissue	O
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	T-1
peripheral	T-1
circulatory	T-1
failure	T-1
and	O
/	O
or	O
hemorrhaging	B-Disease
in	O
various	T-2
parts	T-2
of	T-2
the	T-2
exencephalic	T-2
head	T-2
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	O
of	O
the	O
exencephalic	O
neural	O
tissue	O
causes	T-0
the	T-0
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	T-1
peripheral	T-1
circulatory	B-Disease
failure	I-Disease
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

These	O
findings	O
suggest	O
that	O
overgrowth	T-1
of	T-1
the	O
exencephalic	B-Disease
neural	T-0
tissue	T-0
causes	O
the	O
altered	O
distribution	O
patterns	O
of	O
vessels	O
,	O
subsequent	O
peripheral	O
circulatory	O
failure	O
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	O
head	O
,	O
leading	O
to	O
the	O
multiple	O
modes	O
of	O
tissue	O
reduction	O
during	O
transformation	O
from	O
exencephaly	O
to	O
anencephaly	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
000	O
women	O
00	O
through	O
00	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
0000	O
and	O
0000	O
and	O
000	O
control	O
women	O
who	O
had	O
not	O
had	T-1
a	T-1
myocardial	B-Disease
infarction	I-Disease
and	O
who	O
were	T-0
matched	T-0
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
000	O
women	O
00	O
through	O
00	O
years	O
of	O
age	O
who	O
had	O
had	T-0
a	T-0
first	T-0
myocardial	B-Disease
infarction	I-Disease
between	O
0000	O
and	O
0000	O
and	O
000	O
control	O
women	O
who	O
had	O
not	T-1
had	T-1
a	T-1
myocardial	T-1
infarction	T-1
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	T-0
of	T-0
estrogen	B-Chemical
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
000	O
women	O
00	O
through	O
00	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
0000	O
and	O
0000	O
and	O
000	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	T-1
to	T-1
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	B-Chemical
)	O
oral	O
contraceptives	O
,	O
the	T-0
dose	T-0
of	T-0
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
000	O
women	O
00	O
through	O
00	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
0000	O
and	O
0000	O
and	O
000	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	O
of	O
progestagen	O
included	O
in	O
third	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	T-0
or	T-0
gestodene	B-Chemical
)	O
and	T-1
second	T-1
-	T-1
generation	T-1
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	O
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
000	O
women	O
00	O
through	O
00	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
0000	O
and	O
0000	O
and	O
000	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

We	O
investigated	O
this	O
association	O
,	O
according	O
to	O
the	O
type	T-2
of	T-2
progestagen	B-Chemical
included	T-3
in	T-3
third	T-3
-	T-3
generation	T-3
(	O
i	O
.	O
e	O
.	O
,	O
desogestrel	O
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	O
(	O
i	O
.	O
e	O
.	O
,	O
levonorgestrel	O
)	O
oral	O
contraceptives	O
,	O
the	O
dose	T-4
of	O
estrogen	O
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	O
METHODS	O
:	O
In	O
a	O
nationwide	O
,	O
population	O
-	O
based	O
,	O
case	O
-	O
control	O
study	O
,	O
we	O
identified	O
and	O
enrolled	O
000	O
women	O
00	O
through	O
00	O
years	O
of	O
age	O
who	O
had	O
had	O
a	O
first	O
myocardial	O
infarction	O
between	O
0000	O
and	O
0000	O
and	O
000	O
control	O
women	O
who	O
had	O
not	O
had	O
a	O
myocardial	O
infarction	O
and	O
who	O
were	O
matched	O
for	O
age	O
,	O
calendar	O
year	O
of	O
the	O
index	O
event	O
,	O
and	O
area	O
of	O
residence	O
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neuropathy	B-Disease
were	T-0
reduced	T-1
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	T-0
and	T-0
severity	T-1
of	T-1
cisplatin	O
-	O
induced	O
nephrotoxicity	O
,	O
ototoxicity	B-Disease
,	O
and	O
neuropathy	O
were	T-2
reduced	T-2
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	T-0
nephrotoxicity	B-Disease
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Early	O
trials	O
of	O
cisplatin	O
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	T-2
and	T-2
severity	T-2
of	T-2
cisplatin	B-Chemical
-	O
induced	T-1
nephrotoxicity	T-1
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Early	O
trials	O
of	O
cisplatin	T-0
and	T-0
amifostine	B-Chemical
also	T-1
suggested	T-1
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Early	O
trials	T-0
of	T-0
cisplatin	B-Chemical
and	O
amifostine	O
also	O
suggested	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
cisplatin	O
-	O
induced	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neuropathy	O
were	O
reduced	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	O
(	O
CM	O
)	O
and	O
in	O
elevated	O
plasma	O
lactate	O
(	O
LA	O
)	O
in	O
AIDS	O
through	O
mechanisms	T-0
of	T-0
mitochondrial	B-Disease
dysfunction	I-Disease
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	O
(	O
CM	O
)	O
and	O
in	O
elevated	T-0
plasma	O
lactate	O
(	O
LA	O
)	O
in	O
AIDS	B-Disease
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	O
(	O
CM	O
)	O
and	O
in	O
elevated	T-1
plasma	T-0
lactate	T-0
(	O
LA	B-Chemical
)	O
in	O
AIDS	O
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	O
in	O
cardiomyopathy	O
(	O
CM	O
)	O
and	O
in	O
elevated	T-1
plasma	O
lactate	B-Chemical
(	O
LA	O
)	O
in	T-0
AIDS	T-0
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	T-0
in	O
cardiomyopathy	O
(	O
CM	B-Disease
)	O
and	O
in	O
elevated	O
plasma	O
lactate	O
(	O
LA	O
)	O
in	O
AIDS	O
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
is	O
implicated	T-1
in	T-1
cardiomyopathy	B-Disease
(	T-2
CM	T-2
)	T-2
and	T-0
in	T-0
elevated	T-0
plasma	T-0
lactate	T-0
(	O
LA	O
)	O
in	O
AIDS	O
through	O
mechanisms	O
of	O
mitochondrial	O
dysfunction	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	T-3
-	T-3
induced	T-3
hepatitis	T-3
,	O
associated	O
with	O
the	O
presence	T-2
of	T-2
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	T-4
-	T-4
organ	T-4
failure	T-4
and	T-0
sepsis	B-Disease
,	O
supervened	T-1
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	T-0
by	T-0
multi	B-Disease
-	I-Disease
organ	I-Disease
failure	I-Disease
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	T-0
markers	T-0
of	T-0
autoimmunity	B-Disease
)	O
,	O
and	T-1
accompanied	T-1
by	O
multi	O
-	O
organ	O
failure	O
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	T-0
and	T-0
inguinal	T-0
lymph	T-0
node	T-0
biopsies	T-0
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	B-Disease
-	I-Disease
induced	I-Disease
hepatitis	I-Disease
,	O
associated	T-1
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	O
-	O
organ	O
failure	O
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	O
of	O
severe	O
necrotising	O
lymphadenitis	O
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	B-Disease
drug	I-Disease
reaction	I-Disease
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	T-0
-	T-0
organ	T-0
failure	T-0
and	O
sepsis	O
,	O
supervened	O
.	O

Cervical	O
and	O
inguinal	O
lymph	O
node	O
biopsies	O
showed	O
the	O
features	T-2
of	T-2
severe	T-2
necrotising	T-2
lymphadenitis	B-Disease
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	O
eosinophilic	O
infiltrates	O
,	O
without	O
viral	O
inclusion	O
bodies	O
,	O
suggestive	O
of	O
an	O
adverse	O
drug	O
reaction	O
.	O
A	O
week	O
later	O
,	O
fulminant	O
drug	O
-	O
induced	O
hepatitis	O
,	O
associated	O
with	O
the	O
presence	O
of	O
anti	O
-	O
nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	O
of	O
autoimmunity	O
)	O
,	O
and	O
accompanied	O
by	O
multi	T-1
-	T-1
organ	T-1
failure	T-1
and	O
sepsis	O
,	O
supervened	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	T-1
DTG	T-1
)	T-1
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD0000	O
(	O
0R	O
-	O
0	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
,	O
0	O
-	O
diazabicyclo	O
[	O
0	O
.	O
0	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	T-0
the	O
behavioral	O
toxicity	T-3
of	T-3
cocaine	B-Chemical
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD0000	O
(	O
0R	T-0
-	T-0
0	T-0
-	T-0
[	T-0
0	T-0
-	T-0
(	T-0
0	T-0
,	T-0
0	T-0
-	T-0
dichlorophenyl	T-0
)	T-0
ethyl	T-0
]	O
-	O
0	O
,	O
0	O
-	O
diazabicyclo	O
[	O
0	O
.	O
0	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	T-2
the	O
behavioral	O
toxicity	B-Disease
of	T-3
cocaine	T-3
.	T-2

In	O
contrast	O
to	O
the	O
protection	O
provided	T-1
by	T-1
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	T-3
-	T-3
o	T-3
-	T-3
tolylguanidine	T-3
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD0000	T-4
(	O
0R	B-Chemical
-	I-Chemical
0	I-Chemical
-	I-Chemical
[	I-Chemical
0	I-Chemical
-	I-Chemical
(	I-Chemical
0	I-Chemical
,	I-Chemical
0	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
0	I-Chemical
,	I-Chemical
0	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
0	I-Chemical
.	I-Chemical
0	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	O
each	O
worsened	T-2
the	O
behavioral	T-0
toxicity	T-0
of	O
cocaine	O
.	O

In	O
contrast	O
to	O
the	O
protection	T-2
provided	T-2
by	T-2
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	T-5
sigma	T-5
receptor	T-5
agonist	T-5
BD0000	B-Chemical
(	O
0R	T-0
-	T-0
0	T-0
-	T-0
[	T-0
0	T-0
-	T-0
(	T-0
0	T-0
,	T-0
0	T-0
-	T-0
dichlorophenyl	T-0
)	O
ethyl	T-1
]	O
-	O
0	O
,	O
0	O
-	O
diazabicyclo	O
[	O
0	O
.	O
0	O
.	O
0	O
]	O
nonane	O
)	O
each	T-6
worsened	T-6
the	O
behavioral	T-4
toxicity	T-4
of	O
cocaine	O
.	O

In	O
contrast	T-1
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	T-2
agonist	O
di	O
-	O
o	O
-	O
tolylguanidine	O
(	O
DTG	B-Chemical
)	O
and	O
the	O
novel	T-0
sigma	T-0
receptor	T-0
agonist	T-0
BD0000	T-0
(	O
0R	O
-	O
0	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
,	O
0	O
-	O
diazabicyclo	O
[	O
0	O
.	O
0	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	T-3
of	O
cocaine	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	T-1
by	T-1
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	B-Chemical
-	I-Chemical
o	I-Chemical
-	I-Chemical
tolylguanidine	I-Chemical
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD0000	O
(	O
0R	O
-	O
0	O
-	O
[	O
0	O
-	O
(	O
0	O
,	O
0	O
-	O
dichlorophenyl	O
)	O
ethyl	O
]	O
-	O
0	O
,	O
0	O
-	O
diazabicyclo	O
[	O
0	O
.	O
0	O
.	O
0	O
]	O
nonane	O
)	O
each	O
worsened	T-2
the	O
behavioral	O
toxicity	O
of	O
cocaine	O
.	O

These	O
00	O
included	O
cases	O
of	O
malignant	O
hypertension	O
,	O
thrombotic	O
microangiopathy	O
,	O
lupus	O
nephritis	O
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	O
cocaine	O
-	O
related	T-0
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O

These	O
00	O
included	O
cases	O
of	O
malignant	O
hypertension	O
,	O
thrombotic	O
microangiopathy	O
,	O
lupus	O
nephritis	O
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	T-0
cocaine	B-Chemical
-	O
related	T-1
acute	O
renal	O
failure	O
.	O

These	O
00	O
included	O
cases	T-1
of	T-1
malignant	O
hypertension	O
,	O
thrombotic	O
microangiopathy	O
,	O
lupus	O
nephritis	O
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	T-0
glomerulonephritis	B-Disease
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	O
.	O

These	O
00	O
included	O
cases	O
of	O
malignant	O
hypertension	O
,	O
thrombotic	T-0
microangiopathy	T-0
,	T-0
lupus	B-Disease
nephritis	I-Disease
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	O
.	O

These	O
00	O
included	T-2
cases	O
of	O
malignant	T-0
hypertension	T-0
,	T-0
thrombotic	B-Disease
microangiopathy	I-Disease
,	T-1
lupus	T-1
nephritis	T-1
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	O
.	O

These	O
00	O
included	O
cases	T-1
of	T-1
malignant	B-Disease
hypertension	I-Disease
,	T-0
thrombotic	T-0
microangiopathy	T-0
,	O
lupus	O
nephritis	O
,	O
Henoch	O
-	O
Schonlein	O
nephritis	O
,	O
crescentic	O
glomerulonephritis	O
,	O
and	O
cocaine	O
-	O
related	O
acute	O
renal	O
failure	O
.	O

The	O
authors	O
present	O
a	O
00	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	O
hypotension	O
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
0	O
agonist	O
,	O
for	O
the	T-1
treatment	T-1
of	T-1
spasticity	B-Disease
.	O

The	O
authors	O
present	O
a	O
00	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	T-0
with	T-0
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	O
hypotension	O
following	T-2
the	T-2
addition	T-2
of	T-2
tizanidine	B-Chemical
,	O
an	O
alpha	O
-	O
0	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
00	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	T-0
hypotension	B-Disease
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
0	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
00	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	T-0
control	T-0
hypertension	B-Disease
who	T-1
developed	T-1
hypotension	O
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
0	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

The	O
authors	O
present	O
a	O
00	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	T-1
with	T-1
lisinopril	O
,	O
an	O
angiotensin	B-Chemical
converting	T-2
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	T-3
hypotension	O
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
0	O
agonist	O
,	O
for	T-0
the	T-0
treatment	T-0
of	T-0
spasticity	O
.	O

The	O
authors	O
present	O
a	O
00	O
-	O
year	O
-	O
old	O
boy	O
chronically	O
treated	T-0
with	T-0
lisinopril	B-Chemical
,	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
to	O
control	O
hypertension	O
who	O
developed	O
hypotension	O
following	O
the	O
addition	O
of	O
tizanidine	O
,	O
an	O
alpha	O
-	O
0	O
agonist	O
,	O
for	O
the	O
treatment	O
of	O
spasticity	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	O
(	O
evident	O
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	B-Disease
reaction	I-Disease
(	T-0
one	T-0
patient	T-0
)	T-0
.	O

Minor	O
side	O
effects	O
included	O
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	O
(	O
evident	T-0
as	T-0
ataxic	B-Disease
movements	I-Disease
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	T-1
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	T-1
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	T-2
eight	T-2
of	T-2
the	T-2
thirteen	T-2
patients	T-2
with	T-2
nausea	T-2
)	T-2
,	T-2
clumsiness	B-Disease
(	T-3
evident	T-3
as	T-3
ataxic	T-3
movements	T-3
in	T-3
ten	T-3
patients	T-3
)	T-3
,	O
and	O
dysphoric	O
reaction	T-0
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	T-1
nausea	O
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	B-Disease
)	O
,	O
clumsiness	O
(	O
evident	O
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	T-0
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	O
(	T-0
thirteen	T-0
patients	T-0
)	T-0
,	T-0
emesis	B-Disease
(	T-1
eight	T-1
of	T-1
the	T-1
thirteen	T-1
patients	T-1
with	T-1
nausea	T-1
)	T-1
,	O
clumsiness	O
(	O
evident	O
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	T-2
(	O
one	O
patient	O
)	O
.	O

Minor	O
side	O
effects	O
included	O
nausea	B-Disease
(	O
thirteen	O
patients	O
)	O
,	O
emesis	O
(	O
eight	O
of	O
the	O
thirteen	O
patients	O
with	O
nausea	O
)	O
,	O
clumsiness	O
(	O
evident	O
as	O
ataxic	O
movements	O
in	O
ten	O
patients	O
)	O
,	O
and	O
dysphoric	O
reaction	T-0
(	O
one	O
patient	O
)	O
.	O

Bromocriptine	O
-	O
induced	O
hypotension	O
was	O
unaffected	O
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	O
to	O
significant	O
bradycardia	O
,	O
an	O
effect	T-0
that	O
was	O
partly	O
reduced	T-1
by	O
i	O
.	O
v	O
.	O
domperidone	B-Chemical
(	O
0	O
.	O
0	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	O
hypotension	O
was	O
unaffected	O
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	T-2
to	T-0
significant	T-0
bradycardia	B-Disease
,	O
an	T-1
effect	T-1
that	T-1
was	O
partly	O
reduced	T-3
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
0	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	T-2
hypotension	O
was	O
unaffected	O
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	B-Disease
was	T-1
reversed	T-1
to	T-1
significant	T-1
bradycardia	T-1
,	O
an	O
effect	O
that	O
was	O
partly	T-3
reduced	T-3
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
0	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	O
hypotension	O
was	O
unaffected	T-0
by	T-0
isoproterenol	B-Chemical
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	O
to	O
significant	O
bradycardia	O
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
0	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	O
-	O
induced	T-2
hypotension	B-Disease
was	O
unaffected	T-3
by	T-3
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	T-0
was	O
reversed	O
to	O
significant	O
bradycardia	T-1
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
0	O
mg	O
/	O
kg	O
)	O
.	O

Bromocriptine	B-Chemical
-	O
induced	T-0
hypotension	O
was	T-1
unaffected	T-1
by	O
isoproterenol	O
pretreatment	O
,	O
while	O
tachycardia	O
was	O
reversed	O
to	O
significant	O
bradycardia	O
,	O
an	O
effect	O
that	O
was	O
partly	O
reduced	O
by	O
i	O
.	O
v	O
.	O
domperidone	O
(	O
0	O
.	O
0	O
mg	O
/	O
kg	O
)	O
.	O

Changes	O
of	O
sodium	O
and	O
ATP	O
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	T-0
hypertension	B-Disease
.	O

Changes	T-1
of	T-1
sodium	O
and	O
ATP	O
affinities	T-2
of	T-2
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	T-3
and	T-3
after	T-3
nitric	B-Chemical
oxide	I-Chemical
deficient	T-0
hypertension	O
.	O

Changes	O
of	O
sodium	O
and	O
ATP	O
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
during	T-0
and	O
after	T-1
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	T-0
of	T-0
sodium	O
and	O
ATP	O
affinities	T-1
of	T-1
the	O
cardiac	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	O
of	O
sodium	O
and	T-0
ATP	B-Chemical
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Changes	T-0
of	T-0
sodium	B-Chemical
and	T-1
ATP	O
affinities	O
of	O
the	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
during	O
and	O
after	O
nitric	O
oxide	O
deficient	O
hypertension	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	O
calcification	O
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	O
and	O
susceptibility	O
to	O
artery	O
calcification	O
,	O
with	O
00	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	O
-	O
induced	T-0
artery	B-Disease
calcification	I-Disease
,	O
ie	O
,	O
the	O
00	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	O
calcification	O
and	O
growth	O
status	O
cannot	O
be	O
determined	T-0
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	O
and	O
susceptibility	T-1
to	O
artery	O
calcification	O
,	O
with	O
00	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	T-3
to	T-3
Warfarin	B-Chemical
-	O
induced	T-2
artery	O
calcification	O
,	O
ie	O
,	O
the	O
00	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	O
calcification	O
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	T-0
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	O
and	O
susceptibility	O
to	O
artery	O
calcification	O
,	O
with	O
00	O
%	O
higher	O
levels	O
of	T-2
serum	T-2
phosphate	B-Chemical
in	T-3
young	T-3
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	T-1
to	T-1
Warfarin	O
-	O
induced	O
artery	O
calcification	O
,	O
ie	O
,	O
the	O
00	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	T-1
between	T-1
artery	O
calcification	O
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	T-0
between	T-0
higher	O
serum	O
phosphate	O
and	O
susceptibility	O
to	O
artery	B-Disease
calcification	I-Disease
,	O
with	O
00	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	O
-	O
induced	T-2
artery	O
calcification	O
,	O
ie	O
,	O
the	O
00	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	T-3
young	O
rats	O
.	O

Although	O
the	O
explanation	O
for	O
the	O
association	O
between	O
artery	O
calcification	O
and	O
growth	O
status	O
cannot	T-1
be	T-1
determined	T-1
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	T-0
between	T-0
higher	O
serum	O
phosphate	B-Chemical
and	O
susceptibility	O
to	O
artery	O
calcification	O
,	O
with	O
00	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	T-2
to	T-2
Warfarin	O
-	O
induced	O
artery	O
calcification	O
,	O
ie	O
,	O
the	O
00	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

Although	O
the	O
explanation	O
for	O
the	T-0
association	T-0
between	T-0
artery	B-Disease
calcification	I-Disease
and	O
growth	O
status	O
cannot	O
be	O
determined	O
from	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
relationship	O
between	O
higher	O
serum	O
phosphate	O
and	O
susceptibility	O
to	O
artery	O
calcification	O
,	O
with	O
00	O
%	O
higher	O
levels	O
of	O
serum	O
phosphate	O
in	O
young	O
,	O
ad	O
libitum	O
-	O
fed	O
rats	O
compared	O
with	O
either	O
of	O
the	O
groups	O
that	O
was	O
resistant	O
to	O
Warfarin	O
-	O
induced	O
artery	O
calcification	O
,	O
ie	O
,	O
the	O
00	O
-	O
month	O
-	O
old	O
rats	O
and	O
the	O
restricted	O
-	O
diet	O
,	O
growth	O
-	O
inhibited	O
young	O
rats	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	O
00	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	T-1
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
alone	T-0
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	T-0
mortality	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	O
00	O
mg	O
selegiline	O
per	O
day	O
and	T-2
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
compared	T-1
with	T-1
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	O
00	T-0
mg	T-0
selegiline	B-Chemical
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	O
mortality	O
in	T-0
patients	T-0
with	T-0
Parkinson	O
'	O
s	O
disease	O
(	O
PD	B-Disease
)	O
randomized	O
to	O
receive	O
00	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	O
'	O
s	O
Disease	O
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	T-0
mortality	T-1
in	O
patients	T-2
with	T-2
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	O
)	O
randomized	O
to	O
receive	O
00	O
mg	O
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
The	O
United	O
Kingdom	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Research	O
Group	O
(	O
UKPDRG	O
)	O
trial	O
found	O
an	O
increased	T-1
mortality	T-1
in	T-1
patients	T-1
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
randomized	O
to	O
receive	O
00	T-0
mg	T-0
selegiline	O
per	O
day	O
and	O
L	O
-	O
dopa	O
compared	O
with	O
those	O
taking	O
L	O
-	O
dopa	O
alone	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	T-0
increases	T-1
in	T-1
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	B-Chemical
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	T-0
increases	T-1
in	T-1
nucleus	T-1
accumbens	T-1
(	T-1
NAcc	T-1
)	T-1
dopamine	B-Chemical
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	B-Chemical
-	O
induced	T-1
increases	T-1
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	T-2
low	T-2
dose	T-2
GVG	B-Chemical
on	T-3
cocaine	T-3
-	O
induced	T-1
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	T-0
substance	O
abuse	O
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	B-Disease
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	O
treating	O
substance	O
abuse	O
and	O
the	O
increased	T-0
risk	O
of	O
visual	B-Disease
field	I-Disease
defects	I-Disease
(	O
VFD	O
)	O
associated	T-1
with	T-1
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

OBJECTIVES	O
:	O
Given	O
its	O
preclinical	O
success	O
for	T-0
treating	T-0
substance	B-Disease
abuse	I-Disease
and	O
the	O
increased	O
risk	O
of	O
visual	O
field	O
defects	O
(	O
VFD	O
)	O
associated	O
with	O
cumulative	O
lifetime	O
exposure	O
,	O
we	O
explored	O
the	O
effects	O
of	O
sub	O
-	O
chronic	O
low	O
dose	O
GVG	O
on	O
cocaine	O
-	O
induced	O
increases	O
in	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
dopamine	O
(	O
DA	O
)	O
.	O

Headache	T-0
relief	T-0
at	O
0	O
h	O
was	O
00	O
.	O
0	O
%	O
for	O
rizatriptan	O
and	O
00	O
.	O
0	O
%	O
for	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	B-Chemical
within	O
00	O
min	O
of	O
dosing	T-1
.	O

Headache	O
relief	O
at	O
0	O
h	O
was	O
00	O
.	O
0	O
%	O
for	O
rizatriptan	O
and	O
00	O
.	O
0	O
%	O
for	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	T-0
to	T-0
ergotamine	B-Chemical
/	O
caffeine	O
within	O
00	O
min	O
of	O
dosing	T-1
.	O

Headache	O
relief	O
at	O
0	O
h	O
was	O
00	O
.	O
0	O
%	O
for	O
rizatriptan	O
and	O
00	O
.	O
0	O
%	O
for	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
with	O
rizatriptan	B-Chemical
being	T-0
superior	T-0
to	O
ergotamine	O
/	O
caffeine	O
within	O
00	O
min	O
of	O
dosing	O
.	O

Headache	T-0
relief	T-0
at	O
0	O
h	O
was	O
00	O
.	O
0	O
%	O
for	O
rizatriptan	O
and	O
00	O
.	O
0	O
%	O
for	O
ergotamine	T-1
/	O
caffeine	B-Chemical
(	T-2
p	T-2
<	T-2
or	T-2
=	T-2
0	T-2
.	T-2
000	T-2
)	T-2
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
within	O
00	O
min	O
of	O
dosing	O
.	O

Headache	T-1
relief	T-1
at	O
0	O
h	O
was	O
00	O
.	O
0	O
%	O
for	O
rizatriptan	O
and	O
00	O
.	O
0	O
%	O
for	T-0
ergotamine	B-Chemical
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
within	T-2
00	T-2
min	T-2
of	T-2
dosing	T-2
.	O

Headache	O
relief	O
at	O
0	O
h	O
was	O
00	T-0
.	T-0
0	T-0
%	T-0
for	T-0
rizatriptan	B-Chemical
and	T-1
00	T-1
.	T-1
0	T-1
%	T-1
for	T-1
ergotamine	T-1
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
within	O
00	O
min	O
of	O
dosing	O
.	O

Headache	B-Disease
relief	O
at	O
0	O
h	O
was	O
00	O
.	O
0	O
%	O
for	O
rizatriptan	O
and	O
00	O
.	O
0	O
%	O
for	O
ergotamine	O
/	O
caffeine	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
000	O
)	O
,	O
with	O
rizatriptan	O
being	O
superior	O
to	O
ergotamine	O
/	O
caffeine	O
within	O
00	O
min	O
of	O
dosing	T-0
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	T-1
for	T-1
breast	B-Disease
carcinoma	I-Disease
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	T-1
with	T-1
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	B-Disease
)	O
have	T-0
limited	T-0
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	B-Disease
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	T-0
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	T-2
with	T-2
cisplatin	T-0
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	B-Disease
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	T-1
limited	T-1
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	O
dose	O
-	O
limiting	O
toxicities	O
associated	T-0
with	T-0
cisplatin	B-Chemical
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	O
-	O
response	O
effect	O
has	O
been	O
observed	O
with	O
cisplatin	O
,	O
the	T-0
dose	T-1
-	T-1
limiting	T-1
toxicities	B-Disease
associated	T-2
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Although	O
a	O
dose	T-3
-	T-3
response	T-3
effect	T-3
has	T-1
been	T-1
observed	T-1
with	T-1
cisplatin	B-Chemical
,	O
the	T-2
dose	T-2
-	O
limiting	O
toxicities	O
associated	O
with	O
cisplatin	O
(	O
e	O
.	O
g	O
.	O
,	O
nephrotoxicity	O
,	O
ototoxicity	O
,	O
and	O
neurotoxicity	O
)	O
have	O
limited	O
its	O
use	O
as	O
a	O
treatment	O
for	O
breast	O
carcinoma	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	T-0
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	T-1
properties	T-1
of	O
the	O
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	T-0
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	T-1
properties	T-1
of	T-1
the	T-1
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	T-2
deteriorated	T-2
Na	B-Chemical
+	T-1
-	T-1
binding	T-1
properties	T-1
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	O
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	T-0
Na	B-Chemical
+	O
-	O
extrusion	T-1
from	O
cardiac	O
cells	O
as	O
a	O
consequence	T-2
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	T-0
a	O
reversible	O
hypertension	O
accompanied	T-1
by	T-1
depressed	B-Disease
Na	O
+	O
-	O
extrusion	O
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	O
of	O
NO	O
-	O
synthase	O
induced	T-3
a	T-3
reversible	T-0
hypertension	B-Disease
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	T-1
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	T-2
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

Inhibition	T-2
of	T-2
NO	B-Chemical
-	O
synthase	T-0
induced	T-3
a	O
reversible	O
hypertension	O
accompanied	O
by	O
depressed	O
Na	O
+	O
-	O
extrusion	T-1
from	O
cardiac	O
cells	O
as	O
a	O
consequence	O
of	O
deteriorated	O
Na	O
+	O
-	O
binding	O
properties	O
of	O
the	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	T-0
by	T-0
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	T-1
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	B-Disease
inhibitor	T-2
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	B-Chemical
inhibits	T-1
the	O
activity	T-0
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	T-0

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	T-1
between	T-1
Warfarin	T-0
and	T-0
vitamin	B-Chemical
D	I-Chemical
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	T-3
in	T-3
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	T-0
Warfarin	B-Chemical
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	T-1
by	O
the	O
hypothesis	T-2
that	O
Warfarin	O
inhibits	T-4
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	T-1
by	T-1
vitamin	B-Chemical
D	I-Chemical
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	O
treatment	O
had	O
no	O
effect	T-1
on	T-1
the	O
elevation	O
in	O
serum	T-0
calcium	B-Chemical
produced	T-2
by	T-2
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

Because	O
Warfarin	B-Chemical
treatment	T-0
had	O
no	O
effect	O
on	O
the	O
elevation	O
in	O
serum	O
calcium	O
produced	O
by	O
vitamin	O
D	O
,	O
the	O
synergy	O
between	O
Warfarin	O
and	O
vitamin	O
D	O
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	O
that	O
Warfarin	O
inhibits	O
the	O
activity	O
of	O
matrix	O
Gla	O
protein	O
as	O
a	O
calcification	O
inhibitor	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	T-0
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	T-1
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	T-3
artery	O
calcification	O
through	O
its	O
effect	T-2
on	O
serum	T-4
calcium	B-Chemical
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	T-0
of	T-0
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	T-3
of	T-3
vitamin	O
D	O
dose	O
on	O
the	O
elevation	T-1
of	T-1
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	T-4
induce	T-4
artery	B-Disease
calcification	I-Disease
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	T-0
that	T-0
vitamin	B-Chemical
D	I-Chemical
may	T-1
induce	T-1
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	T-0
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	T-1
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	T-3
of	T-3
serum	O
calcium	B-Chemical
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	T-4
artery	O
calcification	O
through	O
its	O
effect	T-2
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
artery	O
calcification	O
and	O
the	O
effect	T-0
of	T-0
vitamin	B-Chemical
D	I-Chemical
dose	T-1
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	O
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	T-0
effect	T-0
of	T-0
vitamin	O
D	O
dose	T-2
on	O
artery	B-Disease
calcification	I-Disease
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	T-1
that	T-1
vitamin	O
D	O
may	O
induce	O
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

There	O
was	O
a	O
close	O
parallel	O
between	O
the	T-3
effect	T-3
of	T-3
vitamin	B-Chemical
D	I-Chemical
dose	T-4
on	T-4
artery	T-4
calcification	O
and	O
the	O
effect	O
of	O
vitamin	O
D	O
dose	O
on	O
the	O
elevation	O
of	O
serum	O
calcium	O
,	O
which	O
suggests	O
that	O
vitamin	O
D	O
may	O
induce	O
artery	O
calcification	O
through	O
its	O
effect	O
on	O
serum	O
calcium	O
.	O

000	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	T-0
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	T-1
on	T-1
measures	T-2
of	T-2
psychiatric	B-Disease
symptoms	T-3
.	O

000	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	T-2
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	B-Disease
disorder	I-Disease
were	O
compared	T-1
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

000	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	O
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	T-0
mood	B-Disease
disorders	I-Disease
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	T-1

000	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	T-0
mood	O
disorder	O
(	O
CIMD	B-Disease
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

000	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	O
-	O
induced	T-0
mood	B-Disease
disorder	I-Disease
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

000	O
cocaine	O
-	O
dependent	O
outpatients	O
with	O
cocaine	B-Chemical
-	O
induced	T-0
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	O
of	O
psychiatric	O
symptoms	O
.	O

000	O
cocaine	B-Chemical
-	O
dependent	T-1
outpatients	T-1
with	O
cocaine	O
-	O
induced	O
mood	O
disorder	O
(	O
CIMD	O
)	O
,	O
other	O
mood	O
disorders	O
,	O
or	O
no	O
mood	O
disorder	O
were	O
compared	O
on	O
measures	T-0
of	T-0
psychiatric	O
symptoms	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-0
by	T-0
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	T-1
blood	B-Disease
coagulation	I-Disease
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-0
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	T-1
platelet	B-Disease
aggregation	I-Disease
and	T-2
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	T-2
of	T-2
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-3
by	T-3
collagen	O
plus	O
epinephrine	O
(	O
EP	B-Chemical
)	O
in	T-1
mice	T-1
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-1
by	T-1
collagen	O
plus	O
epinephrine	B-Chemical
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	T-2
the	T-2
experimental	T-2
thrombosis	B-Disease
induced	T-1
by	T-1
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	T-0
effects	T-0
of	T-0
TET	O
and	O
FAN	B-Chemical
on	O
the	O
experimental	O
thrombosis	O
induced	O
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
effects	T-1
of	T-1
TET	B-Chemical
and	O
FAN	O
on	O
the	O
experimental	O
thrombosis	O
induced	T-0
by	O
collagen	O
plus	O
epinephrine	O
(	O
EP	O
)	O
in	O
mice	O
,	O
and	O
platelet	O
aggregation	O
and	O
blood	O
coagulation	O
in	O
vitro	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	T-0
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	B-Disease
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	T-0
polycystic	B-Disease
ovary	I-Disease
syndrome	I-Disease
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	T-2
of	O
women	T-0
with	T-0
acne	T-0
and	T-0
hirsutism	B-Disease
and	T-1
is	T-1
also	T-1
a	T-1
treatment	T-1
option	T-1
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	T-0
with	T-0
acne	B-Disease
and	T-1
hirsutism	T-1
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	T-0
with	T-0
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	B-Chemical
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	O
acetate	O
combined	T-0
with	T-0
ethinyl	T-1
estradiol	T-1
(	O
CPA	B-Chemical
/	O
EE	O
)	O
is	T-2
licensed	T-2
in	O
the	O
UK	O
for	O
the	O
treatment	O
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	T-0
acetate	T-0
combined	T-1
with	T-1
ethinyl	B-Chemical
estradiol	I-Chemical
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	T-2
in	T-2
the	O
UK	O
for	T-3
the	T-3
treatment	T-3
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

BACKGROUND	O
:	O
Cyproterone	B-Chemical
acetate	I-Chemical
combined	O
with	O
ethinyl	O
estradiol	O
(	O
CPA	O
/	O
EE	O
)	O
is	O
licensed	T-0
in	O
the	O
UK	O
for	T-1
the	T-1
treatment	T-1
of	O
women	O
with	O
acne	O
and	O
hirsutism	O
and	O
is	O
also	O
a	O
treatment	O
option	O
for	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	T-0
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	T-1
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	T-2
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	T-3
cardiotoxicity	O
by	O
a	O
novel	O
IH000	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	O
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	T-0
cardiotoxicity	B-Disease
by	T-1
a	T-1
novel	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	T-1
acetaminophen	O
-	O
induced	T-2
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	T-3
lung	O
toxicity	O
and	O
doxorubicin	B-Chemical
-	O
induced	T-4
cardiotoxicity	O
by	O
a	O
novel	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	T-1
lung	B-Disease
toxicity	I-Disease
and	T-2
doxorubicin	O
-	O
induced	T-0
cardiotoxicity	O
by	O
a	O
novel	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	B-Chemical
-	O
induced	T-1
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	O
-	T-1
induced	T-1
nephrotoxicity	B-Disease
,	T-2
amiodarone	T-2
-	T-2
induced	T-2
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	O
apoptotic	O
and	O
necrotic	O
cell	O
deaths	O
during	O
acetaminophen	B-Chemical
-	T-0
induced	T-0
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	O
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

In	O
vivo	O
protection	O
of	O
dna	O
damage	O
associated	T-0
apoptotic	T-0
and	O
necrotic	B-Disease
cell	T-2
deaths	T-2
during	O
acetaminophen	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
-	O
induced	T-1
lung	O
toxicity	O
and	O
doxorubicin	O
-	O
induced	O
cardiotoxicity	O
by	O
a	O
novel	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	T-0
of	T-0
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	T-1
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	T-2
with	O
00	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
)	O
for	O
0	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	T-0
in	T-0
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
00	T-1
mg	T-1
/	T-1
kg	T-1
/	T-1
day	T-1
N	B-Chemical
(	I-Chemical
G	I-Chemical
)	I-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
methyl	I-Chemical
ester	I-Chemical
(	O
L	O
-	O
NAME	O
)	O
for	O
0	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	T-1
in	O
rats	O
by	T-2
NO	B-Chemical
-	T-0
synthase	T-0
inhibition	O
with	O
00	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
0	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	B-Disease
induced	T-0
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
00	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
0	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	O
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	B-Chemical
-	O
deficient	O
hypertension	O
induced	T-0
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
00	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
0	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	T-0
of	T-0
cardiac	O
(	O
Na	O
,	O
K	B-Chemical
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	O
with	O
00	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
0	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	O
of	O
Na	O
+	O
,	O
we	O
studied	O
the	O
response	T-0
of	T-0
cardiac	O
(	O
Na	B-Chemical
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	O
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	T-1
with	O
00	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
0	O
four	O
weeks	O
.	O

To	O
assess	O
the	O
molecular	O
basis	O
of	O
disturbances	O
in	O
transmembraneous	O
transport	T-3
of	T-3
Na	B-Chemical
+	O
,	O
we	O
studied	O
the	O
response	T-0
of	O
cardiac	O
(	O
Na	O
,	O
K	O
)	O
-	O
ATPase	O
to	O
NO	O
-	O
deficient	O
hypertension	O
induced	T-1
in	O
rats	O
by	O
NO	O
-	O
synthase	O
inhibition	T-2
with	O
00	O
mg	O
/	O
kg	O
/	O
day	O
N	O
(	O
G	O
)	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
methyl	O
ester	O
(	O
L	O
-	O
NAME	O
)	O
for	O
0	O
four	O
weeks	O
.	O

Allopregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
methyl	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
were	O
tested	T-1
for	O
their	O
ability	O
to	O
suppress	T-2
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	T-0
-	T-0
kindled	T-0
seizures	B-Disease
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
methyl	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	B-Chemical
-	O
kindled	T-0
seizures	T-0
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	T-0
of	T-0
allopregnanolone	T-1
0alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
0beta	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
0alpha	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
00	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
were	T-2
tested	T-2
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	T-2
of	T-2
allopregnanolone	B-Chemical
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
methyl	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
were	T-3
tested	T-3
for	O
their	O
ability	T-0
to	T-0
suppress	T-0
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	T-1
seizures	T-1
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
and	O
ganaxolone	B-Chemical
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
methyl	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
were	T-1
tested	T-1
for	O
their	O
ability	O
to	O
suppress	T-0
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
,	O
pregnanolone	T-1
(	O
0alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
0beta	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
00	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
and	T-2
ganaxolone	T-2
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
methyl	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
were	O
tested	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
,	O
pregnanolone	B-Chemical
(	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
methyl	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
were	O
tested	T-0
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	T-0
(	O
0alpha	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
0alpha	I-Chemical
-	I-Chemical
pregnan	I-Chemical
-	I-Chemical
00	I-Chemical
-	I-Chemical
one	I-Chemical
)	O
,	O
pregnanolone	T-1
(	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
methyl	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
were	T-2
tested	T-2
for	O
their	O
ability	O
to	O
suppress	O
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Allopregnanolone	B-Chemical
(	O
0alpha	O
-	O
hydroxy	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
,	O
pregnanolone	O
(	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
0alpha	O
-	O
hydroxy	O
-	O
0beta	O
-	O
methyl	O
-	O
0alpha	O
-	O
pregnan	O
-	O
00	O
-	O
one	O
)	O
were	O
tested	O
for	O
their	O
ability	T-0
to	T-0
suppress	T-0
the	O
expression	O
(	O
anticonvulsant	O
effect	O
)	O
and	O
development	O
(	O
antiepileptogenic	O
effect	O
)	O
of	O
cocaine	O
-	O
kindled	O
seizures	O
in	O
male	O
,	O
Swiss	O
-	O
Webster	O
mice	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	T-1
stabilizers	T-1
(	O
lithium	B-Chemical
vs	T-0
.	T-0
anticonvulsants	T-0
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	T-1
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	T-2
drugs	T-2
and	O
,	O
more	O
particularly	O
,	O
selective	T-3
serotonin	T-3
reuptake	T-3
inhibitors	T-3
[	O
SSRIs	B-Chemical
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	T-0
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	T-1
with	T-1
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	B-Chemical
drugs	T-0
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	B-Chemical
therapy	T-0
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	B-Disease
episodes	T-0
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	O
or	O
hypomanic	O
switch	O
were	T-0
compared	T-0
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	T-1
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	B-Disease
II	I-Disease
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	T-1
a	O
manic	O
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	B-Disease
-	I-Disease
IV	I-Disease
bipolar	I-Disease
I	I-Disease
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	T-0
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	O
who	O
experienced	O
a	O
manic	T-1
or	T-1
hypomanic	B-Disease
switch	T-0
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	O
during	O
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

Patients	T-1
who	T-1
experienced	T-1
a	T-1
manic	B-Disease
or	T-2
hypomanic	T-2
switch	T-2
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	O
including	O
age	O
,	O
sex	O
,	O
diagnosis	O
(	O
DSM	O
-	O
IV	O
bipolar	O
I	O
vs	O
.	O
bipolar	O
II	O
)	O
,	O
number	O
of	O
previous	O
manic	O
episodes	O
,	O
type	O
of	O
antidepressant	O
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	O
drugs	O
and	O
,	O
more	O
particularly	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	O
of	O
mood	O
stabilizers	O
(	O
lithium	O
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	O
,	O
assessed	T-0
during	T-0
a	O
normothymic	O
period	O
using	O
the	O
hyperthymia	O
component	O
of	O
the	O
Semi	O
-	O
structured	O
Affective	O
Temperament	O
Interview	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	T-0
hemolysis	B-Disease
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	T-0
that	T-0
TAM	B-Chemical
-	O
induced	T-1
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	B-Chemical
)	O
indicating	O
that	O
TAM	O
-	O
induced	T-0
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	T-0
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	T-2
acetate	T-2
(	O
alpha	B-Chemical
-	I-Chemical
TAc	I-Chemical
)	O
(	T-3
inactivated	T-3
functional	T-3
hydroxyl	T-3
)	T-3
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	T-1
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	T-2
of	T-2
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	T-0
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
acetate	I-Chemical
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	T-3
that	T-3
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	T-1
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	T-1
by	O
low	O
concentrations	T-0
of	T-0
alpha	O
-	O
tocopherol	O
(	O
alpha	B-Chemical
-	I-Chemical
T	I-Chemical
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	O
effect	O
of	O
TAM	O
is	O
prevented	T-0
by	O
low	O
concentrations	T-2
of	T-2
alpha	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
(	T-3
alpha	T-3
-	T-3
T	T-3
)	T-3
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	T-1
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
hemolytic	T-2
effect	T-2
of	T-2
TAM	B-Chemical
is	O
prevented	T-1
by	T-1
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	T-0
hemolytic	B-Disease
effect	O
of	O
TAM	O
is	O
prevented	O
by	O
low	O
concentrations	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
T	O
)	O
and	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
alpha	O
-	O
TAc	O
)	O
(	O
inactivated	O
functional	O
hydroxyl	O
)	O
indicating	O
that	O
TAM	O
-	O
induced	O
hemolysis	O
is	O
not	O
related	O
to	O
oxidative	O
membrane	O
damage	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	T-2
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	T-3
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	T-4
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	T-1
given	T-1
GM	B-Chemical
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	T-0
Arabic	T-0
and	O
GM	O
significantly	O
increased	O
creatinine	T-1
and	O
urea	T-2
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	T-3
together	T-3
with	T-3
gum	B-Chemical
Arabic	I-Chemical
than	T-4
in	T-4
those	T-4
given	T-4
GM	T-4
and	T-4
cellulose	T-4
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	T-0
severe	T-0
in	T-0
rats	T-0
given	T-0
GM	B-Chemical
together	T-1
with	T-1
gum	T-1
Arabic	T-1
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	T-0
-	T-0
induced	T-0
proximal	T-0
tubular	B-Disease
necrosis	I-Disease
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	T-0
treatment	T-0
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	T-1
GM	B-Chemical
-	O
induced	T-2
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	T-1
that	O
of	O
cortical	O
GSH	O
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	T-0
the	T-0
cellulose	T-0
plus	T-0
GM	B-Chemical
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	T-0
cortical	T-0
GSH	B-Chemical
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	T-0
treatment	T-0
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	O
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	B-Chemical
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	T-1
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	O
Arabic	O
and	O
GM	O
significantly	O
increased	O
creatinine	O
and	O
urea	B-Chemical
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	T-0
with	T-0
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	O
with	O
gum	T-1
Arabic	T-1
and	T-1
GM	B-Chemical
significantly	T-2
increased	T-2
creatinine	T-2
and	T-2
urea	T-2
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	O
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

The	O
results	O
indicated	O
that	O
concomitant	O
treatment	T-1
with	O
gum	B-Chemical
Arabic	I-Chemical
and	O
GM	O
significantly	T-0
increased	T-0
creatinine	O
and	O
urea	O
by	O
about	O
000	O
and	O
000	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
000	O
and	O
000	O
%	O
,	O
respectively	O
,	O
in	O
rats	O
treated	T-2
with	O
cellulose	O
and	O
GM	O
)	O
,	O
and	O
decreased	O
that	O
of	O
cortical	O
GSH	O
by	O
00	O
%	O
(	O
compared	O
to	O
00	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	O
group	O
)	O
The	O
GM	O
-	O
induced	O
proximal	O
tubular	O
necrosis	O
appeared	O
to	O
be	O
slightly	O
less	O
severe	O
in	O
rats	O
given	O
GM	O
together	O
with	O
gum	O
Arabic	O
than	O
in	O
those	O
given	O
GM	O
and	O
cellulose	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-0
prevent	T-0
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	T-1
cardiotoxicity	B-Disease
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-0
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	T-1
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	B-Chemical
)	O
-	O
induced	T-2
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	B-Chemical
(	T-1
DOX	T-1
)	T-1
-	T-1
induced	T-1
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	T-0
of	T-0
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-1
prevent	T-1
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-2
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	T-4
lung	B-Disease
toxicity	I-Disease
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	T-3
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-1
prevent	T-1
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-2
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	B-Chemical
)	O
-	O
induced	T-0
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	T-0
of	T-0
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-1
prevent	T-1
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-2
nephrotoxicity	O
,	O
amiodarone	B-Chemical
(	O
AMI	O
)	O
-	O
induced	T-3
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	O
acetaminophen	O
(	O
AAP	O
)	O
-	T-1
induced	T-1
nephrotoxicity	B-Disease
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	T-2
prevent	T-2
acetaminophen	O
(	O
AAP	B-Chemical
)	O
-	O
induced	T-3
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	T-1
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	O
(	O
GSPE	O
)	O
to	O
prevent	T-0
acetaminophen	B-Chemical
(	O
AAP	O
)	O
-	O
induced	T-1
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	O
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	T-2
assessed	T-2
the	O
ability	O
of	O
IH000	O
grape	O
seed	O
proanthocyanidin	O
extract	T-0
(	O
GSPE	B-Chemical
)	O
to	T-1
prevent	T-1
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	O
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	O
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	T-3
cardiotoxicity	O
in	O
mice	O
.	O

This	O
study	O
assessed	O
the	O
ability	T-0
of	T-0
IH000	B-Chemical
grape	I-Chemical
seed	I-Chemical
proanthocyanidin	I-Chemical
extract	I-Chemical
(	O
GSPE	O
)	O
to	O
prevent	T-1
acetaminophen	O
(	O
AAP	O
)	O
-	O
induced	T-2
nephrotoxicity	O
,	O
amiodarone	O
(	O
AMI	O
)	O
-	O
induced	T-3
lung	O
toxicity	O
,	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
-	O
induced	T-4
cardiotoxicity	O
in	O
mice	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	T-0
hyperparathyroidism	B-Disease
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	B-Disease
fractures	I-Disease
,	O
and	T-0
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	T-0
foot	B-Disease
deformities	I-Disease
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	T-0
by	T-1
other	T-1
diseases	T-1
causing	O
foot	O
pain	O
,	O
like	T-2
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	B-Disease
claudication	I-Disease
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	T-2
explained	T-2
by	T-2
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	T-0
,	T-0
avascular	B-Disease
necrosis	I-Disease
,	T-1
intermittent	T-1
claudication	T-1
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	T-0
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	B-Disease
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	O
causing	T-0
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	T-1
'	T-1
s	T-1
neuralgia	T-1
,	O
gout	B-Disease
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	T-0
by	T-0
other	O
diseases	O
causing	T-1
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	B-Disease
'	I-Disease
s	I-Disease
neuralgia	I-Disease
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	O
by	O
other	O
diseases	T-0
causing	T-0
foot	T-0
pain	T-0
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	B-Disease
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	O
explained	T-0
by	T-0
other	O
diseases	O
causing	T-1
foot	O
pain	O
,	O
like	O
reflex	B-Disease
sympathetic	I-Disease
dystrophy	I-Disease
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	O
was	O
not	T-0
explained	T-0
by	T-0
other	O
diseases	O
causing	T-1
foot	T-1
pain	B-Disease
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

Pain	B-Disease
was	O
not	O
explained	T-0
by	O
other	O
diseases	O
causing	O
foot	O
pain	O
,	O
like	O
reflex	O
sympathetic	O
dystrophy	O
,	O
polyneuropathy	O
,	O
Morton	O
'	O
s	O
neuralgia	O
,	O
gout	O
,	O
osteoporosis	O
,	O
avascular	O
necrosis	O
,	O
intermittent	O
claudication	O
,	O
orthopaedic	O
foot	O
deformities	O
,	O
stress	O
fractures	O
,	O
and	O
hyperparathyroidism	O
.	O

